<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Skelet Muscle</journal-id><journal-id journal-id-type="iso-abbrev">Skelet Muscle</journal-id><journal-title-group><journal-title>Skeletal Muscle</journal-title></journal-title-group><issn pub-type="epub">2044-5040</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40025502</article-id><article-id pub-id-type="pmc">PMC11871629</article-id>
<article-id pub-id-type="publisher-id">374</article-id><article-id pub-id-type="doi">10.1186/s13395-025-00374-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>OBSCN undergoes extensive alternative splicing during human cardiac and skeletal muscle development</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Oghabian</surname><given-names>Ali</given-names></name><address><email>ali.oghabian@helsinki.fi</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Jonson</surname><given-names>Per Harald</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gayathri</surname><given-names>Swethaa Natraj</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Johari</surname><given-names>Mridul</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Nippala</surname><given-names>Ella</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Andres</surname><given-names>David Gomez</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Munell</surname><given-names>Francina</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Soriano</surname><given-names>Jessica Camacho</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Duran</surname><given-names>Maria Angeles Sanchez</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Sinisalo</surname><given-names>Juha</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Tolppanen</surname><given-names>Heli</given-names></name><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Tolva</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Hackman</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Savarese</surname><given-names>Marco</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Udd</surname><given-names>Bjarne</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05xznzw56</institution-id><institution-id institution-id-type="GRID">grid.428673.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0409 6302</institution-id><institution>Folkh&#x000e4;lsan Research Center, </institution></institution-wrap>Helsinki, Finland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040af2s02</institution-id><institution-id institution-id-type="GRID">grid.7737.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id><institution>Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, </institution></institution-wrap>00014 Helsinki, Finland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040af2s02</institution-id><institution-id institution-id-type="GRID">grid.7737.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id><institution>Department of Medical Genetics, </institution><institution>University of Helsinki, </institution></institution-wrap>Helsinki, Finland </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02xz7d723</institution-id><institution-id institution-id-type="GRID">grid.431595.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0469 0045</institution-id><institution>Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, </institution></institution-wrap>Nedlands, WA Australia </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01d5vx451</institution-id><institution-id institution-id-type="GRID">grid.430994.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1763 0287</institution-id><institution>Pediatric Neuromuscular Unit. Child Neurology Department. Hospital Universitari Vall d&#x02019;Hebron, </institution><institution>Vall d&#x02019;Hebron Research Institute (VHIR) ES, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03ba28x55</institution-id><institution-id institution-id-type="GRID">grid.411083.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0675 8654</institution-id><institution>Histology Department, </institution><institution>Vall d&#x02019;Hebron University Hospital ES, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03ba28x55</institution-id><institution-id institution-id-type="GRID">grid.411083.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0675 8654</institution-id><institution>Prenatal Diagnosis Department, </institution><institution>Vall D&#x02019;hebron University Hospital ES, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052g8jq94</institution-id><institution-id institution-id-type="GRID">grid.7080.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2296 0625</institution-id><institution>Department of Obstetrics, </institution><institution>Maternal Fetal Medicine Unit, Universitat Aut&#x000f2;noma de Barcelona, Hospital Vall D&#x02019;hebron, </institution></institution-wrap>Barcelona, Spain </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040af2s02</institution-id><institution-id institution-id-type="GRID">grid.7737.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id><institution>Helsinki University Central Hospital, </institution></institution-wrap>Helsinki, Finland </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/040af2s02</institution-id><institution-id institution-id-type="GRID">grid.7737.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id><institution>Department of Pathology, </institution><institution>Transplantation Laboratory, University of Helsinki, </institution></institution-wrap>Helsinki, Finland </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/033003e23</institution-id><institution-id institution-id-type="GRID">grid.502801.e</institution-id><institution-id institution-id-type="ISNI">0000 0001 2314 6254</institution-id><institution>Department of Neurology, </institution><institution>Neuromuscular Research Center, Tampere University and University Hospital, </institution></institution-wrap>Tampere, Finland </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><elocation-id>5</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025, corrected publication 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Highly expressed in skeletal muscles, the gene Obscurin (<italic>i.e. OBSCN)</italic> has 121 non-overlapping exons and codes for some of the largest known mRNAs in the human genome. Furthermore, it plays an essential role in muscle development and function. Mutations in <italic>OBSCN</italic> are associated with several hypertrophic cardiomyopathies and muscular disorders. <italic>OBSCN</italic> undergoes extensive and complex alternative splicing, which is the main reason that its splicing regulation associated with skeletal and cardiac muscle development has not previously been thoroughly studied.</p></sec><sec><title>Methods</title><p id="Par2">We analyzed RNA-Seq data from skeletal and cardiac muscles extracted from 44 postnatal individuals and six fetuses. We applied the intron/exon level splicing analysis software IntEREst to study the splicing of <italic>OBSCN</italic> in the studied samples. The differential splicing analysis was adjusted for batch effects. Our comparisons revealed the splicing variations in <italic>OBSCN</italic> between the human skeletal and cardiac muscle, as well as between post-natal muscle (skeletal and cardiac) and the pre-natal equivalent muscle.</p></sec><sec><title>Results</title><p id="Par3">We detected several splicing regulations located in the 5&#x02019;end, 3&#x02019; end, and the middle of <italic>OBSCN</italic> that are associated with human cardiac or skeletal muscle development. Many of these alternative splicing events have not previously been reported. Our results also suggest that many of these muscle-development associated splicing events may be regulated by <italic>BUB3</italic>.</p></sec><sec><title>Conclusions</title><p id="Par4">We conclude that the splicing of <italic>OBSCN</italic> is extensively regulated during the human skeletal/cardiac muscle development. We developed an interactive visualization tool that can be used by clinicians and researchers to study the inclusion of specific OBSCN exons in pre- and postnatal cardiac and skeletal muscles and access the statistics for the differential inclusion of the exons across the studied sample groups. The <italic>OBSCN</italic> exon inclusion map related to the human cardiac and skeletal muscle development is available at <ext-link ext-link-type="uri" xlink:href="http://psivis.it.helsinki.fi:3838/OBSCN_PSIVIS/">http://psivis.it.helsinki.fi:3838/OBSCN_PSIVIS/</ext-link>. These findings are essential for an accurate pre- and postnatal clinical interpretation of the <italic>OBSCN</italic> exonic variants<italic>.</italic></p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13395-025-00374-6.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Neuromuscular diseases</kwd><kwd>OBSCN/RNA splicing</kwd><kwd>Exon inclusion</kwd><kwd>Muscle development</kwd></kwd-group><funding-group><award-group><funding-source><institution>Magnus Ehrnroothin S&#x000e4;&#x000e4;ti&#x000f6;</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>European Joint Program on Rare Diseases</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Instituto de Salud Carlos III</institution></funding-source><award-id>AC19/00048</award-id><principal-award-recipient><name><surname>Nippala</surname><given-names>Ella</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Jane and Aatos Erkko foundation</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Samfundet Folkh&#x000e4;lsan i Svenska Finland</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Academy of Finland</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Syd&#x000e4;ntutkimuss&#x000e4;&#x000e4;ti&#x000f6;</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>University of Helsinki (including Helsinki University Central Hospital)</institution></funding-source></award-group><open-access><p>Open Access funding provided by University of Helsinki (including Helsinki University Central Hospital).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Discovered about two decades ago, the name of the gene Obscurin (<italic>OBSCN</italic>) refers to the challenges that were endured by the researchers in its initial detection and characterization [<xref ref-type="bibr" rid="CR1">1</xref>]. These challenges were mainly caused by the large size and the relatively low abundance of the transcripts in most tissues. With 121 non-overlapping exons, <italic>OBSCN</italic> is indeed one of the genes that code for the largest mRNAs in the human genome. In human, it is expressed at highest levels in skeletal muscles, however it is also highly expressed in cardiac muscles (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). With the relatively high number of exons, we speculate that <italic>OBSCN</italic> undergoes extensive alternative splicing, especially exon skipping. These events are known to result in different mRNAs that code for a family of proteins characterized as &#x0201c;obscurins&#x0201d; [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. The two largest <italic>OBSCN</italic> isoforms are obscurin A and obscurin B [<xref ref-type="bibr" rid="CR3">3</xref>]. They are both characterized by a long stretch of more than 60 immunoglobulin (<italic>i.e.</italic> Ig) repeats that are interrupted by a calmodulin-binding IQ motif and several domains such as fibronectin type-III, SRC homology 3, Rho guanine nucleotide exchange factor and pleckstrin homology. The former (<italic>i.e.</italic>, obscurin A), which is also the smaller of the two (<italic>i.e.</italic>&#x02009;~&#x02009;720&#x000a0;kDa), features a non-modular C-terminal that includes several phosphorylation sites. In contrast, the C-terminus of obscurin B (<italic>i.e.</italic>&#x02009;~&#x02009;870&#x000a0;kDa) features a fibronectin type-III domain, two additional Ig sites and two serine/threonine type kinase sites (for a comprehensive review see Grogan A., et al<italic>.</italic>) [<xref ref-type="bibr" rid="CR3">3</xref>]. Furthermore, other smaller isoforms are reported to be highly abundant in cardiac muscles. Some of these isoforms solely feature an Ig site, a fibronectin type-III site, and one or two kinase domains [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Expression of <italic>OBSCN</italic> in various tissues. Log<sub>10</sub> scaled expression of <italic>OBSCN</italic> across different tissues available in GTEX Analysis Release V8. The curves show the density of the expression values. The horizontal line within the black box shows the median. The black box plots extend vertically from the 25th to the 75th percentile. The outliers are expression levels higher or lower than 1.5 time the interquartile range. GTEx Portal (Analysis Release V8) on 09/13/23</p></caption><graphic xlink:href="13395_2025_374_Fig1_HTML" id="MO1"/></fig></p><p id="Par6">Obscurin is associated with neuromuscular functions such as myofibrillogenesis, hypertrophic response and cytoskeletal arrangements [<xref ref-type="bibr" rid="CR3">3</xref>]. Furthermore, obscurin interacts with the giant sarcomere protein titin [<xref ref-type="bibr" rid="CR6">6</xref>]. In fact, obscurin/titin disrupting mutations are suggested to be the cause of several hypertrophic cardiomyopathies and muscular disorders [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Despite the important role of <italic>OBSCN</italic> in the skeletal muscle development and functioning, to our knowledge, the splicing regulation of <italic>OBSCN</italic> has not yet been studied in detail. In this study, we analyzed 75 pre- and post-natal skeletal muscle and heart (<italic>i.e.</italic> 45 postnatal muscles, 7 postnatal hearts, 20 fetal muscles and 3 fetal hearts) RNAseq data. The fetal samples have been denoted with &#x0201c;F&#x0201d;, and the muscle and heart samples are referred to as &#x0201c;M&#x0201d; and &#x0201c;H&#x0201d; respectively. However, to prevent confusion with &#x0201c;prenatal&#x0201d; we have labelled the postnatal samples with &#x0201c;A&#x0201d; as most of these samples are from adults. In particular, we studied the well-known isoforms of <italic>OBSCN</italic> to quantify and compare the inclusion levels of the <italic>OBSCN</italic> exons across the studied samples. This allowed us to characterize the splicing regulation of <italic>OBSCN</italic> in cardiac and skeletal muscle development by comparing pre- and post-natal samples. As the role of obscurin in muscle diseases is an emerging topic of study [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], a detailed map of the splicing and the expression of various isoforms of this gene is of great importance for the correct interpretation of the effects of novel variants.</p></sec><sec id="Sec2"><title>Results</title><p id="Par7">The prenatal analysis consisted of analyzing inhouse RNA-Seq data from fetal skeletal muscles (<italic>n</italic>&#x02009;=&#x02009;20) and fetal cardiac muscles (<italic>n</italic>&#x02009;=&#x02009;2) from 2 different fetuses (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Additionally, it included analyzing publicly available skeletal muscle data from a 19&#x000a0;weeks female, skeletal muscle data from a 22&#x000a0;weeks male, cardiac muscle data from a 28&#x000a0;weeks female and cardiac muscle data from a 19&#x000a0;weeks female (for more information see &#x02018;<xref rid="Sec9" ref-type="sec">Methods</xref>&#x02019;). For postnatal analysis, RNA-Seq data from an internal cohort of 44 individuals were analyzed (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). We studied six <italic>OBSCN</italic> isoforms, four of which were curated mRNAs and featured NM REFSEQ IDs, <italic>i.e.</italic> ENST00000284548 (NM_052843), ENST00000422127 (NM_001098623), ENST00000570156 (NM_001271223) and ENST00000680850 (NM_001386125). Additionally, we analyzed isoforms ENST00000660857 and ENST00000493977 since they collectively featured four additional unique exons. Overall, we extracted 126 unique or 121 non-overlapping exons from these isoforms, out of which three exons were annotated as alternative first and four exons as alternative last. Additionally, the introns upstream of two exons were annotated with alternative 3&#x02019; splicing (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Internal cohort of individuals whose biopsies were collected for RNA-seq</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><bold>Sex</bold></td><td align="left"><bold>No. samples</bold></td></tr><tr><td align="left">&#x02003;M</td><td align="left">21</td></tr><tr><td align="left">&#x02003;F</td><td align="left">12</td></tr><tr><td align="left">&#x02003;NA</td><td align="left">13</td></tr><tr><td align="left" colspan="2"><bold>Age at biopsy (years)</bold></td></tr><tr><td align="left">&#x02003;0&#x02013;4</td><td align="left">4</td></tr><tr><td align="left">&#x02003;5&#x02013;20</td><td align="left">7</td></tr><tr><td align="left">&#x02003;21&#x02013;60</td><td align="left">25</td></tr><tr><td align="left">&#x02003;&#x0003e;&#x02009;60</td><td align="left">5</td></tr><tr><td align="left">&#x02003;NA</td><td align="left">5</td></tr><tr><td align="left" colspan="2"><bold>Clinical conditions</bold></td></tr><tr><td align="left">&#x02003;Unsolved myopathy</td><td align="left">24</td></tr><tr><td align="left">&#x02003;Myopathy with a genetic diagnosis</td><td align="left">13</td></tr><tr><td align="left">&#x02003;Amputees for myopathy-unrelated reasons</td><td align="left">4</td></tr><tr><td align="left">&#x02003;Hyperckemia without myopathology</td><td align="left">5</td></tr></tbody></table></table-wrap></p><sec id="Sec3"><title>Exon inclusion/skipping</title><p id="Par8">We measured <inline-formula id="IEq1"><alternatives><tex-math id="d33e672">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e677"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq1.gif"/></alternatives></inline-formula> inclusion levels of the 126 <italic>OBSCN</italic> exons for the 45 postnatal skeletal muscle, seven postnatal heart, 20 fetal skeletal muscle and three fetal heart samples. Heatmap (coupled with hierarchical clustering using the &#x0201c;Euclidean&#x0201d; distance) and PCA analysis of <italic>OBSCN</italic> exon inclusion PSI values showed that the samples did not group based on the sex and clinical diagnosis of the studied individuals (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>A,B, Additional File 1). However, overall, a clear distinction of pre- and postnatal skeletal muscles with a less distinction of pre- and postnatal cardiac muscles was observed (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B, and Fig.&#x000a0;S2, Additional File 1). We compared the samples in six different ways: the muscle samples to heart samples (<italic>i.e.</italic> denoted with M), postnatal (i.e. mostly from adult individual) samples to fetal samples (<italic>i.e.</italic> A), postnatal muscle samples to fetal muscle samples (<italic>i.e.</italic> AM/FM), postnatal heart samples to fetal heart samples (<italic>i.e.</italic> AH/FH), postnatal muscle samples to postnatal heart samples (<italic>i.e.</italic> AM/AH), and fetal samples to fetal heart samples (<italic>i.e.</italic> FM/FH) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). We plotted the average <inline-formula id="IEq2"><alternatives><tex-math id="d33e717">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e722"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq2.gif"/></alternatives></inline-formula> levels to detect loci within <italic>OBSCN</italic> where differential splicing was detected when fetal samples were compared to postnatal samples or heart samples were compared to skeletal muscles (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Furthermore, we visualized the distribution of the inclusion levels of the <italic>OBSCN</italic> exons in the studied samples (using box plots), for those exons whose at least two out of the six comparisons (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A) produced significant results (FDR&#x02009;&#x0003c;&#x02009;0.05) with <inline-formula id="IEq3"><alternatives><tex-math id="d33e740">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \psi&#x0003e;10$$\end{document}</tex-math><mml:math id="d33e745"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>&#x003c8;</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq3.gif"/></alternatives></inline-formula> (%)(Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). It is worth noting that for three of the studied exons (<italic>i.e.</italic> exons 48, 53 and 56) significant results were achieved in all comparisons except when postnatal hearts were compared to fetal hearts (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, Table S1, and Fig.&#x000a0;S3, Additional File 1).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Sample comparisons in our study. <bold>A</bold> The RNA-Seq data in our study were analyzed for splicing by comparing the muscle samples to heart samples (denoted with M), mostly adult postnatal samples to fetal samples (denoted with A), mostly adult postnatal muscle samples to fetal muscle samples (denoted also with AM/FM), mostly adult postnatal heart samples to fetal heart samples (AH/FH), mostly adult postnatal muscle samples to mostly adult postnatal heart samples (AM/AH), and fetal samples to fetal heart samples (FM/FH). <bold>B</bold> Scatterplot shows the separation of the studied samples based on <italic>OBSCN</italic> exon inclusion PSI values, by illustrating PC1 vs PC2 (achieved from PCA analysis). The sample types have been labelled with different shapes and colours</p></caption><graphic xlink:href="13395_2025_374_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Inclusion levels of <italic>OBSCN</italic> exons: The plot illustrates the average <inline-formula id="IEq4"><alternatives><tex-math id="d33e789">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e794"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq4.gif"/></alternatives></inline-formula> inclusion levels of the unique exons of <italic>OBSCN</italic> (in the 4 studied sample classes, <italic>i.e.</italic> postnatal muscles, postnatal hearts, fetal muscles and fetal hearts) and the exons are ordered by their start position (<italic>i.e.</italic> X- axis). Each dot shows the average of the <inline-formula id="IEq5"><alternatives><tex-math id="d33e809">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e814"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq5.gif"/></alternatives></inline-formula> values for an <italic>OBSCN</italic> exon within a sample class. The dots are marked by the exon numbers. For those dots that are too close together to distinguish, the ranges of the exon numbers are stated. The average <inline-formula id="IEq6"><alternatives><tex-math id="d33e822">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e827"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq6.gif"/></alternatives></inline-formula> measurements related to a sample class are connected via a line. As their <inline-formula id="IEq7"><alternatives><tex-math id="d33e832">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e837"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq7.gif"/></alternatives></inline-formula> measurements are not accurate (due to the lack of exon-skipping sequence reads), the first and last exons are shown with red triangles and horizontal grey dashed-lines. The variance of the average <inline-formula id="IEq8"><alternatives><tex-math id="d33e842">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e847"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq8.gif"/></alternatives></inline-formula> values (across the different sample classes) are shown (with a purple line) below, in the figure. Exon 126 (i.e. an alternative last exon) is omitted as its start coordinate is identical to that of exon 125</p></caption><graphic xlink:href="13395_2025_374_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Significantly differentially included <italic>OBSCN</italic> exons: <bold>A</bold>-<bold>O</bold>) Ordered by the exon number, the boxplots illustrate the distribution of the <inline-formula id="IEq9"><alternatives><tex-math id="d33e869">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e874"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq9.gif"/></alternatives></inline-formula> levels of the exons that were detected as significant (FDR&#x02009;&#x0003c;&#x02009;0.05) in at least three of the comparisons performed in the study. The box plots extend from the 25th to the 75th percentile, and the thick horizontal line represents the median. The whiskers of the box plots show 1.5 times the interquartile range. The outliers are values higher and lower than the interquartile range. <bold>P</bold>-<bold>R</bold> Sashimi plots, illustrate the exon-exon junctions observed in the RNAseq data, in regions flanking exons 17, 18, 48, 98 and 126. The samples with the nearest PSI values to the median PSI of the exons are chosen for the sashimi plots. <bold>S</bold>-<bold>T</bold> Relative expression levels of the mRNAs that include exons 17 and 18 (S) (based on primers matching junctions Ex16-Ex17 and Ex18-Ex19), and relative expression of the long and short <italic>OBSCN</italic> isoforms (T) (based on analyzing exon-exon junctions specific to these isoforms) are shown with bar plots. These values were measured by real-time polymerase chain reaction (<italic>i.e</italic><italic>.</italic> RT-qPCR) in the postnatal and fetal skeletal muscles. The exon-exon junction levels have been normalized to the total OBSCN mRNA levels (<italic>i.e.</italic> inferred by Ex67-Ex68 junction in <italic>S</italic> and Ex5-Ex6 junction in <italic>T</italic>). The sample classes include: mostly adult postnatal muscles (AM), mostly adult postnatal hearts (AH), fetal muscles (FM), and fetal hearts (FH). The significant levels in the plots are shown using asterisks: <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 (*), <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 (**) and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 (***)</p></caption><graphic xlink:href="13395_2025_374_Fig4_HTML" id="MO4"/></fig></p><p id="Par9">Extensive exon inclusion regulation was detected at several loci at the 5&#x02019; end (exons 17 and 18), the middle (exons 48&#x02013;57) and the 3&#x02019; end of the gene (exons 97 ad 107) that were associated with skeletal muscle development (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref>). The inclusion (or usage) of exon 17 (<italic>FDR(AM/FM)</italic>&#x02009;=&#x02009;<italic>0.00104</italic>, <inline-formula id="IEq10"><alternatives><tex-math id="d33e935">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \Psi$$\end{document}</tex-math><mml:math id="d33e940"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq10.gif"/></alternatives></inline-formula><italic>(AM/FM)</italic>&#x02009;=&#x02009;<italic>-19.2</italic>) and exon 18 (<italic>FDR(AM/FM)</italic>&#x02009;=&#x02009;<italic>0.00236</italic>, <inline-formula id="IEq11"><alternatives><tex-math id="d33e960">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \Psi$$\end{document}</tex-math><mml:math id="d33e965"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq11.gif"/></alternatives></inline-formula><italic>(AM/FM)</italic>&#x02009;=&#x02009;<italic>-18.2</italic>) were noticeably lower in postnatal muscles compared to fetal muscles (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A-B, 4S and Table S2). Interestingly, however, a similar effect was not seen in the postnatal heart compared to the fetal heart tissues (<italic>FDR(AH/FH)</italic>&#x02009;&#x0003e;&#x02009;<italic>0.9</italic>, -5% &#x0003c; <inline-formula id="IEq12"><alternatives><tex-math id="d33e988">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \Psi (AH/FH)$$\end{document}</tex-math><mml:math id="d33e993"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003a8;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>A</mml:mi><mml:mi>H</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>F</mml:mi><mml:mi>H</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq12.gif"/></alternatives></inline-formula> &#x0003c;&#x02009;0%). This leads us to believe that the inclusion of these exons is regulated specifically during skeletal muscle development (and not during heart development). As a result of this exon inclusion decrease, upregulation of the canonical exon junctions <italic>chr1:228243458&#x02013;228246528</italic> (connecting exons 15 and 18) and <italic>chr1:228244571&#x02013;228256651</italic> (connecting exons 16 and 20) were observed in postnatal muscles compared to fetal muscles (<italic>P(AM</italic>&#x02009;&#x0003e;&#x02009;<italic>FM)</italic>&#x02009;=&#x02009;<italic>1e&#x02009;&#x02212;&#x02009;04, 0.0243%</italic> &#x02264; <inline-formula id="IEq13"><alternatives><tex-math id="d33e1027">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \Psi$$\end{document}</tex-math><mml:math id="d33e1032"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq13.gif"/></alternatives></inline-formula>
<italic>EJ(AM/FM)</italic>&#x02009;&#x02264;&#x02009;<italic>0.0485%</italic>) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> A-B, Table S3).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Normalized exon-exon junction levels of non-consecutive exons. Boxplots, illustrating the distribution of the normalized canonical (<bold>A</bold>-<bold>G</bold>) and non-canonical (<bold>H</bold>-<bold>M</bold>) junction levels of non-consecutive exons. If the exon-flanking 5&#x02019; or 3&#x02019; splice site is included in the reference (i.e. GENCODE) the name of the corresponding exon begins with &#x0201c;EX&#x0201d;; otherwise it starts with &#x0201c;ex&#x0201d;. The sample classes include: mostly adult postnatal muscles (AM), mostly adult postnatal hearts (AH), fetal muscles (FM), and fetal hearts (FH). The p-value and <inline-formula id="IEq14"><alternatives><tex-math id="d33e1068">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta EJ$$\end{document}</tex-math><mml:math id="d33e1073"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>E</mml:mi><mml:mi>J</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq14.gif"/></alternatives></inline-formula> values for two sets of comparisons are listed below the box plots: postnatal muscle vs fetal muscle (AM&#x02009;&#x0003e;&#x02009;FM), and postnatal heart vs fetal heart (AH&#x02009;&#x0003e;&#x02009;FH). The Jonckheere Terpstra method was used to test the order and extract the significant results. The significant levels are shown using asterisks: <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 (*), <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 (**) and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 (***). The box plots extend from the 25th to the 75th percentile, and the thick horizontal line represents the median. The whiskers of the boxplots show 1.5 times the interquartile range. The outliers are values higher and lower than the interquartile range</p></caption><graphic xlink:href="13395_2025_374_Fig5_HTML" id="MO5"/></fig></p><p id="Par10">Located in the central region of the <italic>OBSCN</italic> gene, exons 48&#x02013;56 were included significantly less in postnatal muscles than in fetal muscles (<italic>FDR(AM/FM)</italic>&#x02009;&#x0003c;&#x02009;<italic>0.05, </italic><inline-formula id="IEq15"><alternatives><tex-math id="d33e1103">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \psi$$\end{document}</tex-math><mml:math id="d33e1108"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>&#x003c8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq15.gif"/></alternatives></inline-formula><italic>(AM/FM)</italic>&#x02009;&#x0003c;&#x02009;<italic>-10%</italic>) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Although the inclusion levels of these exons were mostly lower in postnatal heart samples than in fetal heart samples (except for exon 52), the effects were milder and the false discovery rates were not significant (FDR(AH/FH)&#x02009;&#x0003e;&#x02009;0.1, <inline-formula id="IEq16"><alternatives><tex-math id="d33e1124">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \psi$$\end{document}</tex-math><mml:math id="d33e1129"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>&#x003c8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq16.gif"/></alternatives></inline-formula>, (AH/FH)&#x02009;&#x0003c;&#x02009;-10%) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, Table S1). We believe that the reason for observing a milder effect in heart is the small size of the fetal heart samples, as the <italic>P</italic>&#x02010;value for some of these effects are less than 0.05 even though their FDR values are not (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref><italic>&#x000a0;K-M</italic>). Furthermore, the inclusion levels for most of these exons (<italic>i.e.</italic> exons 48, 49, 52&#x02013;56, as well as exons 57 and 58) were significantly higher in human muscle samples compared to human heart samples (<italic>FDR(M)</italic>&#x02009;&#x0003c;&#x02009;<italic>0.05, </italic><inline-formula id="IEq17"><alternatives><tex-math id="d33e1156">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \Psi$$\end{document}</tex-math><mml:math id="d33e1161"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq17.gif"/></alternatives></inline-formula><italic>(M)</italic>&#x02009;&#x0003e;&#x02009;<italic>30%</italic>), suggesting that the detection of exon inclusion variations in the cardiac muscles are technically more challenging and require more sequence reads and biological replicates (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Concurrent to these findings, we also noticed significant increase of several canonical as well as a few noncanonical exon junctions in postnatal muscle samples compared to fetal muscle samples (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The upregulated canonical exon junctions were <italic>chr1:228288888&#x02009;&#x02212;&#x02009;228292523</italic> (connecting exons 47 and 49), <italic>chr1:228288888&#x02009;&#x02212;&#x02009;228293353</italic> (connecting exons 47 and 50), and <italic>chr1:228292161&#x02009;&#x02212;&#x02009;228294152</italic> (connecting exons 48 and 51) (Table S3)<italic>.</italic> The upregulated non-canonical exon junctions were <italic>chr1:228293518&#x02009;&#x02212;&#x02009;228294318</italic> (overlapping exons 50 and 51), <italic>chr1:228295020&#x02009;&#x02212;&#x02009;228300123</italic> (overlapping exons 52 and 55)<italic>, and chr1:228300020&#x02009;&#x02212;&#x02009;228303814</italic> (overlapping exon 56) (Table S4)<italic>.</italic></p><p id="Par11">We developed an interactive visualization tool for the exon inclusion <inline-formula id="IEq18"><alternatives><tex-math id="d33e1207">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e1212"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq18.gif"/></alternatives></inline-formula> values using the R Shiny package [<xref ref-type="bibr" rid="CR11">11</xref>] which is available at <ext-link ext-link-type="uri" xlink:href="http://psivis.it.helsinki.fi:3838/OBSCN_PSIVIS/">http://psivis.it.helsinki.fi:3838/OBSCN_PSIVIS/</ext-link>. The software allows the users to zoom into more precise regions within the <italic>OBSCN</italic> gene to view the distribution of the inclusion levels (<italic>i.e.</italic>
<inline-formula id="IEq19"><alternatives><tex-math id="d33e1231">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi )$$\end{document}</tex-math><mml:math id="d33e1236"><mml:mrow><mml:mi mathvariant="normal">&#x003a8;</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq19.gif"/></alternatives></inline-formula> of the exons of interest and the measured statistics.</p></sec><sec id="Sec4"><title>Alternative first/last exons and alternative 3&#x02019; splicing</title><p id="Par12">We measured <inline-formula id="IEq20"><alternatives><tex-math id="d33e1248">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e1253"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq20.gif"/></alternatives></inline-formula> values of the four alternative final exons (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) and two alternative first exons. It is worth noting that the results for exons 126 and 125 (<italic>i.e.</italic> alternative last exons) were reported together as their differences are minor (Table <xref rid="MOESM5" ref-type="media">S5</xref>). Our results showed that exon 98 (<italic>i.e.</italic> exon 95 of the meta-transcript) was included significantly less in the mRNAs of postnatal muscles compared to fetal muscles (<italic>FDR(AM/FM)</italic>&#x02009;=&#x02009;<italic>3.574e&#x02009;&#x02212;&#x02009;19, </italic><inline-formula id="IEq21"><alternatives><tex-math id="d33e1276">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \Psi$$\end{document}</tex-math><mml:math id="d33e1281"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq21.gif"/></alternatives></inline-formula><italic>(AM/FM)</italic>&#x02009;= <italic>&#x02212;&#x02009;36.74%</italic>) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). In contrast, exon 125 or 126 were included significantly more (<italic>FDR(AM/FM)</italic>&#x02009;=&#x02009;<italic>3.419e&#x02009;&#x02212;&#x02009;19, </italic><inline-formula id="IEq22"><alternatives><tex-math id="d33e1303">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \Psi$$\end{document}</tex-math><mml:math id="d33e1308"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq22.gif"/></alternatives></inline-formula><italic>(AM/FM)</italic>&#x02009;=&#x02009;<italic>36.69%</italic>) in the mRNAs of postnatal muscles compared to fetal muscles (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). As a consequence, the skipping of exon 97 (together with exon 98) was significantly upregulated in the postnatal muscles compared to fetal muscles (<italic>P(AM</italic>&#x02009;&#x0003e;&#x02009;<italic>FM)</italic>&#x02009;=&#x02009;<italic>1e&#x02009;&#x02212;&#x02009;04</italic>, <inline-formula id="IEq23"><alternatives><tex-math id="d33e1334">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta$$\end{document}</tex-math><mml:math id="d33e1339"><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq23.gif"/></alternatives></inline-formula>
<italic>EJ(AM/FM)</italic>&#x02009;=&#x02009;<italic>0.34%</italic>) (Figs.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>J, <xref rid="Fig4" ref-type="fig">4</xref>T). These findings, together with the real-time polymerase chain reaction (RT-qPCR) results, indicate a higher abundance of the longer isoform obscurin-B in the postnatal skeletal muscles despite the higher abundance of the shorter isoform obscurin-A in the fetal skeletal muscles (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>T, Table S6).
</p><p id="Par13">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>The studied <italic>OBSCN</italic> isoforms and exons</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Exon number</th><th align="left">Meta transcript exon number</th><th align="left">Chr</th><th align="left">Begin</th><th align="left">End</th><th align="left">Strand</th><th align="left">ENST00000284548</th><th align="left">ENST00000422127</th><th align="left">ENST00000493977</th><th align="left">ENST00000570156</th><th align="left">ENST00000660857</th><th align="left">ENST00000680850</th><th align="left">First exon</th><th align="left">Last exon</th><th align="left">Alternative splicing</th><th align="left">Start Phase</th><th align="left">End Phase</th><th align="left">Domain</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">1</td><td align="left">chr1</td><td align="left">228208044</td><td align="left">228208185</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">1</td><td align="left"/><td align="left">1</td><td align="left">TRUE</td><td align="left">FALSE</td><td align="left"/><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">2</td><td align="left">1a</td><td align="left">chr1</td><td align="left">228208063</td><td align="left">228208185</td><td align="left">+</td><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">TRUE</td><td align="left">FALSE</td><td align="left"/><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">3</td><td align="left">1b</td><td align="left">chr1</td><td align="left">228208130</td><td align="left">228208185</td><td align="left">+</td><td align="left"/><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">TRUE</td><td align="left">FALSE</td><td align="left"/><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">4</td><td align="left">2</td><td align="left">chr1</td><td align="left">228211766</td><td align="left">228212771</td><td align="left">+</td><td align="left">2</td><td align="left">2</td><td align="left"/><td align="left">2</td><td align="left"/><td align="left">2</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">-</td><td align="left">1</td><td align="left">Ig #1, Ig #2, Ig#3</td></tr><tr><td align="left">5</td><td align="left">3</td><td align="left">chr1</td><td align="left">228213441</td><td align="left">228213710</td><td align="left">+</td><td align="left">3</td><td align="left">3</td><td align="left"/><td align="left">3</td><td align="left"/><td align="left">3</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #4</td></tr><tr><td align="left">6</td><td align="left">4</td><td align="left">chr1</td><td align="left">228214174</td><td align="left">228214434</td><td align="left">+</td><td align="left">4</td><td align="left">4</td><td align="left"/><td align="left">4</td><td align="left"/><td align="left">4</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #5</td></tr><tr><td align="left">7</td><td align="left">5</td><td align="left">chr1</td><td align="left">228214790</td><td align="left">228215098</td><td align="left">+</td><td align="left">5</td><td align="left">5</td><td align="left"/><td align="left">5</td><td align="left"/><td align="left">5</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Fn3 #1</td></tr><tr><td align="left">8</td><td align="left">6</td><td align="left">chr1</td><td align="left">228215563</td><td align="left">228215829</td><td align="left">+</td><td align="left">6</td><td align="left">6</td><td align="left"/><td align="left">6</td><td align="left"/><td align="left">6</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #6</td></tr><tr><td align="left">9</td><td align="left">6a</td><td align="left">chr1</td><td align="left">228215689</td><td align="left">228215829</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left">1</td><td align="left"/><td align="left"/><td align="left"/><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #6</td></tr><tr><td align="left">10</td><td align="left">7</td><td align="left">chr1</td><td align="left">228216421</td><td align="left">228216702</td><td align="left">+</td><td align="left">7</td><td align="left">7</td><td align="left">2</td><td align="left">7</td><td align="left"/><td align="left">7</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #7</td></tr><tr><td align="left">11</td><td align="left">8</td><td align="left">chr1</td><td align="left">228217013</td><td align="left">228217288</td><td align="left">+</td><td align="left">8</td><td align="left">8</td><td align="left">3</td><td align="left">8</td><td align="left"/><td align="left">8</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #8</td></tr><tr><td align="left">12</td><td align="left">9</td><td align="left">chr1</td><td align="left">228217395</td><td align="left">228218222</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left">4</td><td align="left"/><td align="left"/><td align="left"/><td align="left">FALSE</td><td align="left">TRUE</td><td align="left"><p>AL=chr1:228359597-228361250:+,</p><p>AL=chr1:228378618-228378874:+,</p><p>AL=chr1:228378618-228378876:+</p></td><td align="left">1</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">13</td><td align="left">10</td><td align="left">chr1</td><td align="left">228219324</td><td align="left">228219599</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">9</td><td align="left"/><td align="left">9</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #9</td></tr><tr><td align="left">14</td><td align="left">11</td><td align="left">chr1</td><td align="left">228224459</td><td align="left">228224734</td><td align="left">+</td><td align="left">9</td><td align="left">9</td><td align="left"/><td align="left">10</td><td align="left"/><td align="left">10</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #10</td></tr><tr><td align="left">15</td><td align="left">12</td><td align="left">chr1</td><td align="left">228243183</td><td align="left">228243458</td><td align="left">+</td><td align="left">10</td><td align="left">10</td><td align="left"/><td align="left">11</td><td align="left"/><td align="left">11</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #11</td></tr><tr><td align="left">16</td><td align="left">13</td><td align="left">chr1</td><td align="left">228244296</td><td align="left">228244571</td><td align="left">+</td><td align="left">11</td><td align="left">11</td><td align="left"/><td align="left">12</td><td align="left"/><td align="left">12</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #12</td></tr><tr><td align="left">17</td><td align="left">14</td><td align="left">chr1</td><td align="left">228245413</td><td align="left">228245688</td><td align="left">+</td><td align="left">12</td><td align="left">12</td><td align="left"/><td align="left">13</td><td align="left"/><td align="left">13</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #13</td></tr><tr><td align="left">18</td><td align="left">15</td><td align="left">chr1</td><td align="left">228246528</td><td align="left">228246803</td><td align="left">+</td><td align="left">13</td><td align="left">13</td><td align="left"/><td align="left">14</td><td align="left"/><td align="left">14</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #14</td></tr><tr><td align="left">19</td><td align="left">16</td><td align="left">chr1</td><td align="left">228249965</td><td align="left">228250240</td><td align="left">+</td><td align="left">14</td><td align="left">14</td><td align="left"/><td align="left">15</td><td align="left"/><td align="left">15</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #15</td></tr><tr><td align="left">20</td><td align="left">17</td><td align="left">chr1</td><td align="left">228256651</td><td align="left">228256926</td><td align="left">+</td><td align="left">15</td><td align="left">15</td><td align="left"/><td align="left">16</td><td align="left"/><td align="left">16</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #16</td></tr><tr><td align="left">21</td><td align="left">18</td><td align="left">chr1</td><td align="left">228259501</td><td align="left">228259776</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">17</td><td align="left"/><td align="left">17</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #17</td></tr><tr><td align="left">22</td><td align="left">19</td><td align="left">chr1</td><td align="left">228264116</td><td align="left">228264391</td><td align="left">+</td><td align="left">16</td><td align="left">16</td><td align="left"/><td align="left">18</td><td align="left"/><td align="left">18</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #18</td></tr><tr><td align="left">23</td><td align="left">20</td><td align="left">chr1</td><td align="left">228268530</td><td align="left">228268805</td><td align="left">+</td><td align="left">17</td><td align="left">17</td><td align="left"/><td align="left">19</td><td align="left"/><td align="left">19</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #19</td></tr><tr><td align="left">24</td><td align="left">21</td><td align="left">chr1</td><td align="left">228271925</td><td align="left">228272221</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">20</td><td align="left"/><td align="left">20</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #20</td></tr><tr><td align="left">25</td><td align="left">22</td><td align="left">chr1</td><td align="left">228273272</td><td align="left">228273547</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">21</td><td align="left"/><td align="left">21</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #21</td></tr><tr><td align="left">26</td><td align="left">23</td><td align="left">chr1</td><td align="left">228273770</td><td align="left">228274048</td><td align="left">+</td><td align="left">18</td><td align="left">18</td><td align="left"/><td align="left">22</td><td align="left"/><td align="left">22</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Fn3 #2</td></tr><tr><td align="left">27</td><td align="left">24</td><td align="left">chr1</td><td align="left">228274178</td><td align="left">228274444</td><td align="left">+</td><td align="left">19</td><td align="left">19</td><td align="left"/><td align="left">23</td><td align="left"/><td align="left">23</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #22</td></tr><tr><td align="left">28</td><td align="left">25</td><td align="left">chr1</td><td align="left">228274572</td><td align="left">228274841</td><td align="left">+</td><td align="left">20</td><td align="left">20</td><td align="left"/><td align="left">24</td><td align="left"/><td align="left">24</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #23</td></tr><tr><td align="left">29</td><td align="left">26</td><td align="left">chr1</td><td align="left">228275760</td><td align="left">228276026</td><td align="left">+</td><td align="left">21</td><td align="left">21</td><td align="left"/><td align="left">25</td><td align="left"/><td align="left">25</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #24</td></tr><tr><td align="left">30</td><td align="left">27</td><td align="left">chr1</td><td align="left">228276450</td><td align="left">228276716</td><td align="left">+</td><td align="left">22</td><td align="left">22</td><td align="left"/><td align="left">26</td><td align="left"/><td align="left">26</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #25</td></tr><tr><td align="left">31</td><td align="left">28</td><td align="left">chr1</td><td align="left">228276930</td><td align="left">228277042</td><td align="left">+</td><td align="left">23</td><td align="left">23</td><td align="left"/><td align="left">27</td><td align="left"/><td align="left">27</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">0</td><td align="left">&#x000bd; Ig #26</td></tr><tr><td align="left">32</td><td align="left">29</td><td align="left">chr1</td><td align="left">228277160</td><td align="left">228277313</td><td align="left">+</td><td align="left">24</td><td align="left">24</td><td align="left"/><td align="left">28</td><td align="left"/><td align="left">28</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">1</td><td align="left">&#x000bd; Ig #26</td></tr><tr><td align="left">33</td><td align="left">30</td><td align="left">chr1</td><td align="left">228277505</td><td align="left">228277666</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">29</td><td align="left"/><td align="left">29</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">&#x000bd; Ig #27</td></tr><tr><td align="left">34</td><td align="left">31</td><td align="left">chr1</td><td align="left">228277754</td><td align="left">228277858</td><td align="left">+</td><td align="left">25</td><td align="left">25</td><td align="left"/><td align="left">30</td><td align="left"/><td align="left">30</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">&#x000bd; Ig #27</td></tr><tr><td align="left">35</td><td align="left">32</td><td align="left">chr1</td><td align="left">228278689</td><td align="left">228278955</td><td align="left">+</td><td align="left">26</td><td align="left">26</td><td align="left"/><td align="left">31</td><td align="left"/><td align="left">31</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #28</td></tr><tr><td align="left">36</td><td align="left">33</td><td align="left">chr1</td><td align="left">228279175</td><td align="left">228279444</td><td align="left">+</td><td align="left">27</td><td align="left">27</td><td align="left"/><td align="left">32</td><td align="left"/><td align="left">32</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #28 few AAs</td></tr><tr><td align="left">37</td><td align="left">34</td><td align="left">chr1</td><td align="left">228279821</td><td align="left">228280087</td><td align="left">+</td><td align="left">28</td><td align="left">28</td><td align="left"/><td align="left">33</td><td align="left"/><td align="left">33</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #29</td></tr><tr><td align="left">38</td><td align="left">35</td><td align="left">chr1</td><td align="left">228280179</td><td align="left">228280445</td><td align="left">+</td><td align="left">29</td><td align="left">29</td><td align="left"/><td align="left">34</td><td align="left"/><td align="left">34</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #30</td></tr><tr><td align="left">39</td><td align="left">36</td><td align="left">chr1</td><td align="left">228280530</td><td align="left">228280796</td><td align="left">+</td><td align="left">30</td><td align="left">30</td><td align="left"/><td align="left">35</td><td align="left"/><td align="left">35</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #31</td></tr><tr><td align="left">40</td><td align="left">37</td><td align="left">chr1</td><td align="left">228281933</td><td align="left">228282205</td><td align="left">+</td><td align="left">31</td><td align="left">31</td><td align="left"/><td align="left">36</td><td align="left"/><td align="left">36</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #32</td></tr><tr><td align="left">41</td><td align="left">38</td><td align="left">chr1</td><td align="left">228283018</td><td align="left">228283284</td><td align="left">+</td><td align="left">32</td><td align="left">32</td><td align="left"/><td align="left">37</td><td align="left"/><td align="left">37</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #33</td></tr><tr><td align="left">42</td><td align="left">39</td><td align="left">chr1</td><td align="left">228283503</td><td align="left">228283769</td><td align="left">+</td><td align="left">33</td><td align="left">33</td><td align="left"/><td align="left">38</td><td align="left"/><td align="left">38</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #34</td></tr><tr><td align="left">43</td><td align="left">40</td><td align="left">chr1</td><td align="left">228286078</td><td align="left">228286350</td><td align="left">+</td><td align="left">34</td><td align="left">34</td><td align="left"/><td align="left">39</td><td align="left"/><td align="left">39</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #35</td></tr><tr><td align="left">44</td><td align="left">41</td><td align="left">chr1</td><td align="left">228286773</td><td align="left">228287039</td><td align="left">+</td><td align="left">35</td><td align="left">35</td><td align="left"/><td align="left">40</td><td align="left"/><td align="left">40</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #36</td></tr><tr><td align="left">45</td><td align="left">42</td><td align="left">chr1</td><td align="left">228287694</td><td align="left">228287960</td><td align="left">+</td><td align="left">36</td><td align="left">36</td><td align="left"/><td align="left">41</td><td align="left"/><td align="left">41</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #37</td></tr><tr><td align="left">46</td><td align="left">43</td><td align="left">chr1</td><td align="left">228288061</td><td align="left">228288324</td><td align="left">+</td><td align="left">37</td><td align="left">37</td><td align="left"/><td align="left">42</td><td align="left"/><td align="left">42</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #38</td></tr><tr><td align="left">47</td><td align="left">44</td><td align="left">chr1</td><td align="left">228288625</td><td align="left">228288888</td><td align="left">+</td><td align="left">38</td><td align="left">38</td><td align="left"/><td align="left">43</td><td align="left"/><td align="left">43</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #39</td></tr><tr><td align="left">48</td><td align="left">45</td><td align="left">chr1</td><td align="left">228291898</td><td align="left">228292161</td><td align="left">+</td><td align="left">39</td><td align="left">39</td><td align="left"/><td align="left">44</td><td align="left"/><td align="left">44</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #40</td></tr><tr><td align="left">49</td><td align="left">46</td><td align="left">chr1</td><td align="left">228292523</td><td align="left">228292786</td><td align="left">+</td><td align="left">40</td><td align="left">40</td><td align="left"/><td align="left">45</td><td align="left"/><td align="left">45</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #41</td></tr><tr><td align="left">50</td><td align="left">47</td><td align="left">chr1</td><td align="left">228293353</td><td align="left">228293616</td><td align="left">+</td><td align="left">41</td><td align="left">41</td><td align="left"/><td align="left">46</td><td align="left"/><td align="left">46</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #42</td></tr><tr><td align="left">51</td><td align="left">48</td><td align="left">chr1</td><td align="left">228294152</td><td align="left">228294415</td><td align="left">+</td><td align="left">42</td><td align="left">42</td><td align="left"/><td align="left">47</td><td align="left"/><td align="left">47</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #43</td></tr><tr><td align="left">52</td><td align="left">49</td><td align="left">chr1</td><td align="left">228294780</td><td align="left">228295043</td><td align="left">+</td><td align="left">43</td><td align="left">43</td><td align="left"/><td align="left">48</td><td align="left"/><td align="left">48</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #44</td></tr><tr><td align="left">53</td><td align="left">50</td><td align="left">chr1</td><td align="left">228298454</td><td align="left">228298717</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">49</td><td align="left"/><td align="left">49</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #45</td></tr><tr><td align="left">54</td><td align="left">51</td><td align="left">chr1</td><td align="left">228299259</td><td align="left">228299522</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">50</td><td align="left"/><td align="left">50</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #46</td></tr><tr><td align="left">55</td><td align="left">52</td><td align="left">chr1</td><td align="left">228299882</td><td align="left">228300145</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">51</td><td align="left"/><td align="left">51</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #47</td></tr><tr><td align="left">56</td><td align="left">53</td><td align="left">chr1</td><td align="left">228303675</td><td align="left">228303938</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">52</td><td align="left"/><td align="left">52</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #48</td></tr><tr><td align="left">57</td><td align="left">54</td><td align="left">chr1</td><td align="left">228304303</td><td align="left">228304566</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">53</td><td align="left"/><td align="left">53</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #49</td></tr><tr><td align="left">58</td><td align="left">55</td><td align="left">chr1</td><td align="left">228305123</td><td align="left">228305386</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">54</td><td align="left"/><td align="left">54</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #50</td></tr><tr><td align="left">59</td><td align="left">56</td><td align="left">chr1</td><td align="left">228306372</td><td align="left">228306638</td><td align="left">+</td><td align="left">44</td><td align="left">44</td><td align="left"/><td align="left">55</td><td align="left"/><td align="left">55</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #51</td></tr><tr><td align="left">60</td><td align="left">57</td><td align="left">chr1</td><td align="left">228306901</td><td align="left">228307167</td><td align="left">+</td><td align="left">45</td><td align="left">45</td><td align="left"/><td align="left">56</td><td align="left"/><td align="left">56</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #52</td></tr><tr><td align="left">61</td><td align="left">58</td><td align="left">chr1</td><td align="left">228307259</td><td align="left">228307531</td><td align="left">+</td><td align="left">46</td><td align="left">46</td><td align="left"/><td align="left">57</td><td align="left"/><td align="left">57</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #53</td></tr><tr><td align="left">62</td><td align="left">59</td><td align="left">chr1</td><td align="left">228308111</td><td align="left">228308383</td><td align="left">+</td><td align="left">47</td><td align="left">47</td><td align="left"/><td align="left">58</td><td align="left"/><td align="left">58</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #54</td></tr><tr><td align="left">63</td><td align="left">60</td><td align="left">chr1</td><td align="left">228309099</td><td align="left">228309295</td><td align="left">+</td><td align="left">48</td><td align="left">48</td><td align="left"/><td align="left">59</td><td align="left"/><td align="left">59</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">0</td><td align="left">&#x000bd;Ig #55</td></tr><tr><td align="left">64</td><td align="left">61</td><td align="left">chr1</td><td align="left">228309484</td><td align="left">228309559</td><td align="left">+</td><td align="left">49</td><td align="left">49</td><td align="left"/><td align="left">60</td><td align="left">1</td><td align="left">60</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">1</td><td align="left">&#x000bd;Ig #55</td></tr><tr><td align="left">65</td><td align="left">62</td><td align="left">chr1</td><td align="left">228313614</td><td align="left">228313886</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">2</td><td align="left"/><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #56</td></tr><tr><td align="left">66</td><td align="left">63</td><td align="left">chr1</td><td align="left">228314814</td><td align="left">228315080</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3</td><td align="left"/><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #57</td></tr><tr><td align="left">67</td><td align="left">64</td><td align="left">chr1</td><td align="left">228315847</td><td align="left">228316119</td><td align="left">+</td><td align="left">50</td><td align="left">50</td><td align="left"/><td align="left">61</td><td align="left">4</td><td align="left">61</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #58</td></tr><tr><td align="left">68</td><td align="left">65</td><td align="left">chr1</td><td align="left">228316709</td><td align="left">228316984</td><td align="left">+</td><td align="left">51</td><td align="left">51</td><td align="left"/><td align="left">62</td><td align="left"/><td align="left">62</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #59</td></tr><tr><td align="left">69</td><td align="left">66</td><td align="left">chr1</td><td align="left">228317464</td><td align="left">228317751</td><td align="left">+</td><td align="left">52</td><td align="left">52</td><td align="left"/><td align="left">63</td><td align="left"/><td align="left">63</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Fn3</td></tr><tr><td align="left">70</td><td align="left">67</td><td align="left">chr1</td><td align="left">228317892</td><td align="left">228318173</td><td align="left">+</td><td align="left">53</td><td align="left">53</td><td align="left"/><td align="left">64</td><td align="left"/><td align="left">64</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #60</td></tr><tr><td align="left">71</td><td align="left">68</td><td align="left">chr1</td><td align="left">228318884</td><td align="left">228319254</td><td align="left">+</td><td align="left">54</td><td align="left">54</td><td align="left"/><td align="left">65</td><td align="left"/><td align="left">65</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">0</td><td align="left">-</td></tr><tr><td align="left">72</td><td align="left">69</td><td align="left">chr1</td><td align="left">228321344</td><td align="left">228322214</td><td align="left">+</td><td align="left">55</td><td align="left">55</td><td align="left"/><td align="left">66</td><td align="left"/><td align="left">66</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">1</td><td align="left">IQ, Ig #61</td></tr><tr><td align="left">73</td><td align="left">70</td><td align="left">chr1</td><td align="left">228323328</td><td align="left">228323606</td><td align="left">+</td><td align="left">56</td><td align="left">56</td><td align="left"/><td align="left">67</td><td align="left"/><td align="left">67</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">Ig #62</td></tr><tr><td align="left">74</td><td align="left">71</td><td align="left">chr1</td><td align="left">228332860</td><td align="left">228332938</td><td align="left">+</td><td align="left">57</td><td align="left">57</td><td align="left"/><td align="left">68</td><td align="left"/><td align="left">68</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">2</td><td align="left">-</td></tr><tr><td align="left">75</td><td align="left">72</td><td align="left">chr1</td><td align="left">228333199</td><td align="left">228333323</td><td align="left">+</td><td align="left">58</td><td align="left">58</td><td align="left"/><td align="left">69</td><td align="left"/><td align="left">69</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">1</td><td align="left">&#x000bd; Ig #63</td></tr><tr><td align="left">76</td><td align="left">73</td><td align="left">chr1</td><td align="left">228333583</td><td align="left">228333780</td><td align="left">+</td><td align="left">59</td><td align="left">59</td><td align="left"/><td align="left">70</td><td align="left"/><td align="left">70</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">&#x000bd; Ig #63</td></tr><tr><td align="left">77</td><td align="left">74</td><td align="left">chr1</td><td align="left">228334512</td><td align="left">228334544</td><td align="left">+</td><td align="left">60</td><td align="left">60</td><td align="left"/><td align="left">71</td><td align="left"/><td align="left">71</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left">78</td><td align="left">75</td><td align="left">chr1</td><td align="left">228334815</td><td align="left">228334913</td><td align="left">+</td><td align="left">61</td><td align="left">61</td><td align="left"/><td align="left">72</td><td align="left"/><td align="left">72</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">&#x000bd; Ig #64</td></tr><tr><td align="left">79</td><td align="left">76</td><td align="left">chr1</td><td align="left">228335080</td><td align="left">228335298</td><td align="left">+</td><td align="left">62</td><td align="left">62</td><td align="left"/><td align="left">73</td><td align="left"/><td align="left">73</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">&#x000bd; Ig #64</td></tr><tr><td align="left">80</td><td align="left">77</td><td align="left">chr1</td><td align="left">228335791</td><td align="left">228335851</td><td align="left">+</td><td align="left">63</td><td align="left">63</td><td align="left"/><td align="left">74</td><td align="left"/><td align="left">74</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">2</td><td align="left">-</td></tr><tr><td align="left">81</td><td align="left">78</td><td align="left">chr1</td><td align="left">228336200</td><td align="left">228336270</td><td align="left">+</td><td align="left">64</td><td align="left">64</td><td align="left"/><td align="left">75</td><td align="left"/><td align="left">75</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left">82</td><td align="left">79</td><td align="left">chr1</td><td align="left">228337004</td><td align="left">228337126</td><td align="left">+</td><td align="left">65</td><td align="left">65</td><td align="left"/><td align="left">76</td><td align="left"/><td align="left">76</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left">83</td><td align="left">80</td><td align="left">chr1</td><td align="left">228337244</td><td align="left">228337383</td><td align="left">+</td><td align="left">66</td><td align="left">66</td><td align="left"/><td align="left">77</td><td align="left"/><td align="left">77</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">0</td><td align="left">-</td></tr><tr><td align="left">84</td><td align="left">81</td><td align="left">chr1</td><td align="left">228337944</td><td align="left">228338144</td><td align="left">+</td><td align="left">67</td><td align="left">67</td><td align="left"/><td align="left">78</td><td align="left"/><td align="left">78</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">0</td><td align="left">SH3</td></tr><tr><td align="left">85</td><td align="left">82</td><td align="left">chr1</td><td align="left">228338290</td><td align="left">228338372</td><td align="left">+</td><td align="left">68</td><td align="left">68</td><td align="left"/><td align="left">79</td><td align="left"/><td align="left">79</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">2</td><td align="left">-</td></tr><tr><td align="left">86</td><td align="left">83</td><td align="left">chr1</td><td align="left">228338853</td><td align="left">228339026</td><td align="left">+</td><td align="left">69</td><td align="left">69</td><td align="left"/><td align="left">80</td><td align="left"/><td align="left">80</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">2</td><td align="left">DH</td></tr><tr><td align="left">87</td><td align="left">84</td><td align="left">chr1</td><td align="left">228339945</td><td align="left">228340101</td><td align="left">+</td><td align="left">70</td><td align="left">70</td><td align="left"/><td align="left">81</td><td align="left"/><td align="left">81</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">0</td><td align="left">DH</td></tr><tr><td align="left">88</td><td align="left">85</td><td align="left">chr1</td><td align="left">228340506</td><td align="left">228340622</td><td align="left">+</td><td align="left">71</td><td align="left">71</td><td align="left"/><td align="left">82</td><td align="left"/><td align="left">82</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">0</td><td align="left">DH</td></tr><tr><td align="left">89</td><td align="left">86</td><td align="left">chr1</td><td align="left">228340724</td><td align="left">228340888</td><td align="left">+</td><td align="left">72</td><td align="left">72</td><td align="left"/><td align="left">83</td><td align="left"/><td align="left">83</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">0</td><td align="left">DH</td></tr><tr><td align="left">90</td><td align="left">87</td><td align="left">chr1</td><td align="left">228341095</td><td align="left">228341253</td><td align="left">+</td><td align="left">73</td><td align="left">73</td><td align="left"/><td align="left">84</td><td align="left"/><td align="left">84</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">0</td><td align="left">PH</td></tr><tr><td align="left">91</td><td align="left">88</td><td align="left">chr1</td><td align="left">228341437</td><td align="left">228341614</td><td align="left">+</td><td align="left">74</td><td align="left">74</td><td align="left"/><td align="left">85</td><td align="left"/><td align="left">85</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">1</td><td align="left">PH</td></tr><tr><td align="left">92</td><td align="left">89</td><td align="left">chr1</td><td align="left">228342119</td><td align="left">228342232</td><td align="left">+</td><td align="left">75</td><td align="left">75</td><td align="left"/><td align="left">86</td><td align="left"/><td align="left">86</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">&#x000bd; Ig #65</td></tr><tr><td align="left">93</td><td align="left">90</td><td align="left">chr1</td><td align="left">228349890</td><td align="left">228350057</td><td align="left">+</td><td align="left">76</td><td align="left">76</td><td align="left"/><td align="left">87</td><td align="left"/><td align="left">87</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">&#x000bd;Ig #65</td></tr><tr><td align="left">94</td><td align="left">91</td><td align="left">chr1</td><td align="left">228350841</td><td align="left">228350943</td><td align="left">+</td><td align="left">77</td><td align="left">77</td><td align="left"/><td align="left">88</td><td align="left"/><td align="left">88</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">2</td><td align="left">1/3 Ig #66</td></tr><tr><td align="left">95</td><td align="left">92</td><td align="left">chr1</td><td align="left">228351321</td><td align="left">228351450</td><td align="left">+</td><td align="left">78</td><td align="left">78</td><td align="left"/><td align="left">89</td><td align="left"/><td align="left">89</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">0</td><td align="left">1/3 Ig #66</td></tr><tr><td align="left">96</td><td align="left">93</td><td align="left">chr1</td><td align="left">228352951</td><td align="left">228353062</td><td align="left">+</td><td align="left">79</td><td align="left">79</td><td align="left"/><td align="left">90</td><td align="left"/><td align="left">90</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">1</td><td align="left">1/3 Ig #66</td></tr><tr><td align="left">97</td><td align="left">94</td><td align="left">chr1</td><td align="left">228356151</td><td align="left">228356193</td><td align="left">+</td><td align="left">80</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">2</td><td align="left">-</td></tr><tr><td align="left">98</td><td align="left">95</td><td align="left">chr1</td><td align="left">228359597</td><td align="left">228361250</td><td align="left">+</td><td align="left">81</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">FALSE</td><td align="left">TRUE</td><td align="left"><p>AL=chr1:228217395-228218222:+,</p><p>AL=chr1:228378618-228378874:+,</p><p>AL=chr1:228378618-228378876:+</p></td><td align="left">2</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">99</td><td align="left">96</td><td align="left">chr1</td><td align="left">228362576</td><td align="left">228362755</td><td align="left">+</td><td align="left"/><td align="left">80</td><td align="left"/><td align="left">91</td><td align="left"/><td align="left">91</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left">100</td><td align="left">97</td><td align="left">chr1</td><td align="left">228364981</td><td align="left">228365077</td><td align="left">+</td><td align="left"/><td align="left">81</td><td align="left"/><td align="left">92</td><td align="left"/><td align="left">92</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">2</td><td align="left">-</td></tr><tr><td align="left">101</td><td align="left">98</td><td align="left">chr1</td><td align="left">228365436</td><td align="left">228365560</td><td align="left">+</td><td align="left"/><td align="left">82</td><td align="left"/><td align="left">93</td><td align="left"/><td align="left">93</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left">102</td><td align="left">99</td><td align="left">chr1</td><td align="left">228366074</td><td align="left">228366186</td><td align="left">+</td><td align="left"/><td align="left">83</td><td align="left"/><td align="left">94</td><td align="left"/><td align="left">94</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">0</td><td align="left">&#x000bd; Ig #67</td></tr><tr><td align="left">103</td><td align="left">100</td><td align="left">chr1</td><td align="left">228366400</td><td align="left">228366568</td><td align="left">+</td><td align="left"/><td align="left">84</td><td align="left"/><td align="left">95</td><td align="left"/><td align="left">95</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">1</td><td align="left">&#x000bd; Ig #67</td></tr><tr><td align="left">104</td><td align="left">101</td><td align="left">chr1</td><td align="left">228366808</td><td align="left">228366889</td><td align="left">+</td><td align="left"/><td align="left">85</td><td align="left"/><td align="left">96</td><td align="left"/><td align="left">96</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">2</td><td align="left">Kinase #1</td></tr><tr><td align="left">105</td><td align="left">102</td><td align="left">chr1</td><td align="left">228366975</td><td align="left">228367175</td><td align="left">+</td><td align="left"/><td align="left">86</td><td align="left"/><td align="left">97</td><td align="left"/><td align="left">97</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">2</td><td align="left">Kinase #1</td></tr><tr><td align="left">106</td><td align="left">103</td><td align="left">chr1</td><td align="left">228367886</td><td align="left">228367946</td><td align="left">+</td><td align="left"/><td align="left">87</td><td align="left"/><td align="left">98</td><td align="left"/><td align="left">98</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">0</td><td align="left">Kinase #1</td></tr><tr><td align="left">107</td><td align="left">104</td><td align="left">chr1</td><td align="left">228368339</td><td align="left">228368416</td><td align="left">+</td><td align="left"/><td align="left">88</td><td align="left"/><td align="left">99</td><td align="left"/><td align="left">99</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">0</td><td align="left">Kinase #1</td></tr><tr><td align="left">108</td><td align="left">105</td><td align="left">chr1</td><td align="left">228368722</td><td align="left">228368894</td><td align="left">+</td><td align="left"/><td align="left">89</td><td align="left"/><td align="left">100</td><td align="left"/><td align="left">100</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">2</td><td align="left">Kinase #1</td></tr><tr><td align="left">109</td><td align="left">106</td><td align="left">chr1</td><td align="left">228369136</td><td align="left">228369162</td><td align="left">+</td><td align="left"/><td align="left">90</td><td align="left"/><td align="left">101</td><td align="left"/><td align="left">101</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">2</td><td align="left">Kinase #1</td></tr><tr><td align="left">110</td><td align="left">107</td><td align="left">chr1</td><td align="left">228369942</td><td align="left">228370094</td><td align="left">+</td><td align="left"/><td align="left">91</td><td align="left"/><td align="left">102</td><td align="left"/><td align="left">102</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">2</td><td align="left">Kinase #1</td></tr><tr><td align="left">111</td><td align="left">108</td><td align="left">chr1</td><td align="left">228370193</td><td align="left">228370238</td><td align="left">+</td><td align="left"/><td align="left">92</td><td align="left"/><td align="left">103</td><td align="left"/><td align="left">103</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">0</td><td align="left">Kinase #1</td></tr><tr><td align="left">112</td><td align="left">109</td><td align="left">chr1</td><td align="left">228370679</td><td align="left">228370756</td><td align="left">+</td><td align="left"/><td align="left">93</td><td align="left"/><td align="left">104</td><td align="left"/><td align="left">104</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">0</td><td align="left">-</td></tr><tr><td align="left">113</td><td align="left">110</td><td align="left">chr1</td><td align="left">228371023</td><td align="left">228373081</td><td align="left">+</td><td align="left"/><td align="left">94</td><td align="left"/><td align="left">105</td><td align="left"/><td align="left">105</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">0</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left">114</td><td align="left">111</td><td align="left">chr1</td><td align="left">228373932</td><td align="left">228374012</td><td align="left">+</td><td align="left"/><td align="left">95</td><td align="left"/><td align="left">106</td><td align="left"/><td align="left">106</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left">115</td><td align="left">112</td><td align="left">chr1</td><td align="left">228374314</td><td align="left">228374424</td><td align="left">+</td><td align="left"/><td align="left">96</td><td align="left"/><td align="left">107</td><td align="left"/><td align="left">107</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">&#x000bd; Ig #68</td></tr><tr><td align="left">116</td><td align="left">113</td><td align="left">chr1</td><td align="left">228374585</td><td align="left">228374752</td><td align="left">+</td><td align="left"/><td align="left">97</td><td align="left"/><td align="left">108</td><td align="left"/><td align="left">108</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">&#x000bd; Ig #68</td></tr><tr><td align="left">117</td><td align="left">114</td><td align="left">chr1</td><td align="left">228375702</td><td align="left">228375824</td><td align="left">+</td><td align="left"/><td align="left">98</td><td align="left"/><td align="left">109</td><td align="left"/><td align="left">109</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left">118</td><td align="left">115</td><td align="left">chr1</td><td align="left">228376008</td><td align="left">228376178</td><td align="left">+</td><td align="left"/><td align="left">99</td><td align="left"/><td align="left">110</td><td align="left"/><td align="left">110</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left">119</td><td align="left">116</td><td align="left">chr1</td><td align="left">228376793</td><td align="left">228376874</td><td align="left">+</td><td align="left"/><td align="left">100</td><td align="left"/><td align="left">111</td><td align="left"/><td align="left">111</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">1</td><td align="left">2</td><td align="left">Kinase #2</td></tr><tr><td align="left">120</td><td align="left">117</td><td align="left">chr1</td><td align="left">228377052</td><td align="left">228377291</td><td align="left">+</td><td align="left"/><td align="left">101</td><td align="left"/><td align="left">112</td><td align="left"/><td align="left">112</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">2</td><td align="left">Kinase #2</td></tr><tr><td align="left">121</td><td align="left">118</td><td align="left">chr1</td><td align="left">228377489</td><td align="left">228377712</td><td align="left">+</td><td align="left"/><td align="left">102</td><td align="left"/><td align="left">113</td><td align="left"/><td align="left">113</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">1</td><td align="left">Kinase #2</td></tr><tr><td align="left">122</td><td align="left">119</td><td align="left">chr1</td><td align="left">228377931</td><td align="left">228378006</td><td align="left">+</td><td align="left"/><td align="left">103</td><td align="left"/><td align="left"/><td align="left"/><td align="left">114</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left">A5'=chr1:228377937-228378006:+</td><td align="left">1</td><td align="left">2</td><td align="left">Kinase #2</td></tr><tr><td align="left">123</td><td align="left">119a</td><td align="left">chr1</td><td align="left">228377937</td><td align="left">228378006</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">114</td><td align="left"/><td align="left"/><td align="left">FALSE</td><td align="left">FALSE</td><td align="left">A5'=chr1:228377931-228378006:+</td><td align="left">1</td><td align="left">2</td><td align="left">Kinase #2</td></tr><tr><td align="left">124</td><td align="left">120</td><td align="left">chr1</td><td align="left">228378271</td><td align="left">228378420</td><td align="left">+</td><td align="left"/><td align="left">104</td><td align="left"/><td align="left">115</td><td align="left"/><td align="left">115</td><td align="left">FALSE</td><td align="left">FALSE</td><td align="left"/><td align="left">2</td><td align="left">2</td><td align="left">Kinase #2</td></tr><tr><td align="left">125</td><td align="left">121a</td><td align="left">chr1</td><td align="left">228378618</td><td align="left">228378874</td><td align="left">+</td><td align="left"/><td align="left">105</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">FALSE</td><td align="left">TRUE</td><td align="left"><p>AL=chr1:228217395-228218222:+,</p><p>AL=chr1:228359597-228361250:+,</p><p>AL=chr1:228378618-228378876:+</p></td><td align="left">2</td><td align="left">-</td><td align="left">Kinase #2</td></tr><tr><td align="left">126</td><td align="left">121</td><td align="left">chr1</td><td align="left">228378618</td><td align="left">228378876</td><td align="left">+</td><td align="left"/><td align="left"/><td align="left"/><td align="left">116</td><td align="left"/><td align="left">116</td><td align="left">FALSE</td><td align="left">TRUE</td><td align="left"><p>AL=chr1:228217395-228218222:+,</p><p>AL=chr1:228359597-228361250:+,</p><p>AL=chr1:228378618-228378874:+</p></td><td align="left">2</td><td align="left">-</td><td align="left">Kinase #2</td></tr></tbody></table><table-wrap-foot><p>Each row of the table represents a unique OBSCN exon. The unique exon IDs based on the non-overlapping exons are listed below the &#x0201c;Meta-transcript exon number&#x0201d;. The six studied transcripts include ENST00000284548, ENST00000422127, ENST00000570156, ENST00000680850, ENST00000660857 and ENST00000493977. Below the columns labelled with the Ensembl IDs, for those exons included in the isoform, the number of the exons are stated. In the columns labelled with &#x0201c;First exon&#x0201d; and &#x0201c;Last exon&#x0201d;, the cells corresponding to the first and last exon of the isoform are marked with TRUE. The final fours columns (i.e. on the right) include the detailed information about the alternative splicing events, and the annotated domains</p></table-wrap-foot></table-wrap></p><p id="Par14">
<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>The inclusion of the alternative last exons in OBSCN mRNAs. The boxplots, illustrate the distribution of the <inline-formula id="IEq24"><alternatives><tex-math id="d33e5798">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e5803"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq24.gif"/></alternatives></inline-formula> levels of the alternative last exons. The sample classes for which the <inline-formula id="IEq25"><alternatives><tex-math id="d33e5808">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e5813"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq25.gif"/></alternatives></inline-formula> values are shown are: muscle vs heart (M), mostly adult postnatal vs fetal (A), postnatal muscle vs fetal muscle samples (AM/FM), postnatal heart vs fetal heart samples (AH/FH), postnatal muscle vs postnatal heart samples (AM/AH), and fetal muscle vs fetal heart samples (FM/FH). The significant levels are shown using asterisks: <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 (*), <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01 (**) and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001 (***). They are coloured in red if <inline-formula id="IEq26"><alternatives><tex-math id="d33e5828">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\left|\Delta \psi \right|\ge 10$$\end{document}</tex-math><mml:math id="d33e5833"><mml:mrow><mml:mfenced close="|" open="|"><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi>&#x003c8;</mml:mi></mml:mfenced><mml:mo>&#x02265;</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq26.gif"/></alternatives></inline-formula>. The box plots extend from the 25th to the 75th percentile, and the thick horizontal line represents the median. The whiskers of the boxplots show 1.5 times the interquartile range. The outliers are values higher and lower than the interquartile range. Since their start coordinates are identical, the <inline-formula id="IEq27"><alternatives><tex-math id="d33e5843">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e5848"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq27.gif"/></alternatives></inline-formula> values for the exons 125 (i.e. 121a of meta-transcript, <italic>chr1: 228378618&#x02013;228378874</italic>) and 126 (i.e. 121 of meta-transcript, <italic>chr1: 228378618&#x02013;228378876</italic>) are indistinguishable, therefore reported together</p></caption><graphic xlink:href="13395_2025_374_Fig6_HTML" id="MO7"/></fig></p><p id="Par15">We also studied the alternative 3&#x02019; splicing related to the exons 122 and 123 (<italic>i.e.</italic> 119 and 119a of meta-transcript, respectively) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). The inclusion levels of exon 123 (i.e. 119a of meta-transcript) were very low and the upstream intron was rarely spliced across our studied samples, suggesting that almost all mRNAs in our samples included the alternative exon 122 (i.e. 119 of meta-transcript) (Fig. S4, Additional File 1&#x0feff;).</p></sec><sec id="Sec5"><title>The affected protein domains</title><p id="Par16">The exons 17 and 18 that were frequently skipped in the adult skeletal muscle samples are known to code for Ig domains (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Furthermore, the exons 48&#x02013;56 that were less included in the postnatal skeletal and cardiac muscles compared to the equivalent prenatal samples, also code for Ig domains (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). As mentioned earlier, our results showed higher abundance of the longer <italic>OBSCN</italic> isoform (<italic>e.g.</italic> obscurin-B) compared to the shorter isoform (<italic>e.g.</italic> obscurin-A) in postnatal skeletal muscles, even though the shorter isoform was more abundant in fetal skeletal muscles. Compared to the short isoform (<italic>i.e.</italic> obscurin-A), the long isoform (<italic>i.e.</italic> obscurin-B) features an addition fibronectin type-III domain, two additional Ig sites and two serine/threonine type kinase sites. These variations in the domains can change the chemical/physical properties of a protein and ultimately affect its function.</p></sec><sec id="Sec6"><title>Regulation of OBSCN exon inclusion by the splicing factors</title><p id="Par17">We examined the Spearman (rank) correlation of the expression of the significantly differentially expressed splicing factors (when comparing postnatal to fetal muscle samples) with the inclusion <inline-formula id="IEq28"><alternatives><tex-math id="d33e5899">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e5904"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq28.gif"/></alternatives></inline-formula> values of the <italic>OBSCN</italic> exons that were significantly differentially included (in postnatal muscle vs fetal muscle) across the studied skeletal muscle samples. Several significant correlations (|<italic>rho</italic>|&#x0003e;&#x02009;0.4, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05) were detected, <italic>e.g.</italic> expression of <italic>DHX15</italic>, <italic>THOC1</italic>, PRPF1 with inclusion levels of exon 17 and 49 (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A-J, Table S7-S10). However, remarkably the expression of <italic>BUB3</italic> was significantly correlated with the inclusion levels of most of the significantly differentially included exons (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A-I). The BUB3 gene belongs to the budding uninhibited by benomyl (BUB) protein family and is involved in mitosis, aging, carcinogenesis, as well as splicing [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Our results suggest the possibility of regulation of <italic>OBSCN</italic> splicing by <italic>BUB3</italic> especially during muscle development.<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Correlation of the <italic>OBSCN</italic> exon inclusion levels with the expression of several splicing factors. <bold>A</bold>&#x000a0;The rank correlation of the expression of the significantly differentially expressed splicing factors (comparing postnatal muscles vs fetal muscles) with the inclusion levels of the exons that were significantly differentially included (also when comparing postnatal muscles vs fetal muscles) have been shown as a matrix of circles (i.e. correlation plots). The significant (<italic>i.e. P</italic>&#x02009;&#x0003c;&#x02009;0.05) correlations have only been shown. The size and the colour of the circles represent the correlation (<italic>i.e. rho</italic> value) of the corresponding splice factor (labelled on the row) with the corresponding OBSCN exon (labelled on the column). The <italic>rho</italic> values higher than 0.4 or lower than -0.4 have also been written. <bold>B</bold>-<bold>J</bold>&#x000a0;For a highly correlated pair (<italic>i.e. |rho|</italic>&#x0003e;&#x02009;0.5, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05), the two lines in the plot show the PSI values of the OBSCN exon, as well as the VST normalized expression levels of the splicing factor (scaled to 100) across the studied samples</p></caption><graphic xlink:href="13395_2025_374_Fig7_HTML" id="MO8"/></fig></p></sec></sec><sec id="Sec7"><title>Discussion</title><p id="Par18">Alternative splicing plays an essential role in the regulation of gene expression during organ development in mammalians. It is known that throughout the different stages of human life, a great number of genes are differentially spliced, especially in tissues such as brain and heart [<xref ref-type="bibr" rid="CR14">14</xref>]. Here we studied <italic>OBSCN</italic>, a gene associated with neuromuscular function that has 121 non-overlapping (or 126 unique) exons and codes for some of the largest mRNAs in the human genome. <italic>OBSCN</italic> is upregulated in aged skeletal muscle myofiber fragments (<italic>e.g.</italic> MF-IIsc) and RASA4&#x02009;+&#x02009;myocytes (Table S10) [<xref ref-type="bibr" rid="CR15">15</xref>]. However, we studied the splicing regulation of <italic>OBSCN</italic> during human skeletal and cardiac muscle development. Given the large number of exons in the gene, we hypothesized that it undergoes extensive alternative splicing regulation during muscle and heart development. As a result, we discovered several alternative splicing events in <italic>OBSCN</italic> associated with skeletal and cardiac muscle development. These mainly included cassette exons and alternative last exon usage events that were significantly differential in the postnatal human skeletal and cardiac muscles, compared to the equivalent prenatal tissues.</p><p id="Par19">The splicing event that was most frequently differential across our pre- and postnatal cardiac, and skeletal muscle samples was exon inclusion (Figs. <xref rid="Fig3" ref-type="fig">3</xref> and <xref rid="Fig4" ref-type="fig">4</xref>). The predominance of the exon inclusion (and exon skipping) was not surprising as in previous studies this splicing event has been the most frequent out of all the significant alternative splicing events found in mammals and vertebrates [<xref ref-type="bibr" rid="CR16">16</xref>]. Also in-line with these findings, exon skipping has been reported as the most frequently regulated event during the development of seven organs (including heart) in six mammals (including human) and a bird [<xref ref-type="bibr" rid="CR14">14</xref>]. In mice muscles, extensive differential gene expression and alternative splicing has been discovered to occur during the first two weeks after birth, with the vast majority of these alternative splicing events (<italic>i.e.</italic> 77%) being exon skipping [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par20">In this study, we discovered extensive exon inclusion regulation at several loci, at the 5&#x02019; end, the middle and the 3&#x02019; end of <italic>OBSCN</italic> gene that are associated with cardiac or skeletal muscle development. Exons 48&#x02013;56 of <italic>OBSCN</italic> were significantly less included in RNAs in the postnatal muscles compared to the fetal muscles (<italic>FDR(AM/FM)</italic>&#x02009;&#x0003c;&#x02009;<italic>0.05, </italic><inline-formula id="IEq29"><alternatives><tex-math id="d33e6046">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \Psi$$\end{document}</tex-math><mml:math id="d33e6051"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq29.gif"/></alternatives></inline-formula><italic>(AM/FM)</italic>&#x02009;&#x0003c;&#x02009;<italic>-10%</italic>) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C-M). A similar, albeit milder, effect was also seen in cardiac muscles (<italic>FDR(AH/FH)</italic>&#x02009;&#x0003e;&#x02009;<italic>0.05, </italic><inline-formula id="IEq30"><alternatives><tex-math id="d33e6073">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Delta \Psi$$\end{document}</tex-math><mml:math id="d33e6078"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:mrow></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq30.gif"/></alternatives></inline-formula><italic>(AH/FH)</italic>&#x02009;&#x0003c;&#x02009;<italic>0%</italic>) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C-M). It is worth mentioning that from this region of <italic>OBSCN</italic> (<italic>i.e.</italic> exons 48&#x02013;56), exons 48&#x02013;54 have previously been reported to undergo developmentally dynamic alternative splicing, especially during human heart development [<xref ref-type="bibr" rid="CR14">14</xref>]. A dynamic alternative splicing event is a splicing event whose PSI changes in the studied tissue (e.g. heart) during human life is greater than 20% [<xref ref-type="bibr" rid="CR14">14</xref>]. Another exon inclusion regulation, exhibiting strong effects in human muscle development and mild effects in human heart development, was seen <italic>in</italic> exons 17 and 18 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A,B). Additionally we noticed significant increase in several canonical as well as a few non-canonical exon junction levels in postnatal muscles compared to fetal muscles. To our knowledge the association of these alternative splicing events with human skeletal muscle development has not previously been reported. We also discovered several splicing factors (<italic>e.g. DHX15</italic>, <italic>THOC1</italic>, <italic>PRPF1, BUB3)</italic> whose expression levels were significantly correlated (<italic>P</italic>&#x02009;&#x0003c;&#x02009;<italic>0.05</italic> and <italic>|rho|</italic>&#x02265;&#x02009;<italic>0.4</italic>) with the inclusion levels of the significantly differentially included exons (when comparing postnatal to fetal muscles) (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A-J). Our results suggest that the differential inclusion of the <italic>OBSCN</italic> exons during skeletal muscle development may be regulated by <italic>BUB3</italic>. In fact, Bub3 and BuGZ are two essential mitotic regulators that together interact with the splicing machinery in the interphase nucleus [<xref ref-type="bibr" rid="CR13">13</xref>]. Silencing of either Bub3 or BuGZ has previously shown to enhance exon skipping in Human foreskin fibroblast (<italic>i.e.</italic> HFF) and ovarian carcinoma TOV21G cell lines [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, BugZ was not differentially expressed (in postnatal skeletal muscles compared to prenatal skeletal muscles), therefore it is likely that the exon inclusion effects that we report are caused by the differential expression of Bub3 (Table S10). However, it is worth noting that due to scarcity of prior knock-down studies, especially in human muscle samples, a thorough analysis (beyond the scope of this study) is necessary before the precise role of Bub3 in RNA splicing, in muscles of human and other species can be concluded.</p><p id="Par21">In addition to exon skipping, we discovered an alternative last exon usage event that is associated with skeletal muscle development. We discovered that the <italic>OBSCN</italic> isoform that ends with exon 98 (e.g. obscurin-A) is expressed much higher in fetal skeletal muscles, whereas the larger isoform that skip exons 97 and 98 and end with either exon 125 or exon 126 (e.g. obscurin-B) is more expressed in postnatal skeletal muscles (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>T and <xref rid="Fig6" ref-type="fig">6</xref>). To our knowledge the higher abundance of the longer <italic>OBSCN</italic> isoform in postnatal muscles compared to fetal muscles has neither been reported earlier.</p><p id="Par22">Almost all the significantly differentially included exons detected in our study code for immunoglobulin domains. Similar to that in titin, obscurin feature long repeats of Ig domains (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) and these tandem Ig domains are mostly coded by individual exons (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Therefore, not surprisingly, the most affected (<italic>i.e.</italic> skipped) exons in our samples code for a complete (not partial) Ig domain (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Even though the function of the repeated Ig domains in sarcomeric genes (<italic>e.g. OBSCN</italic> and <italic>TTN</italic>) has not thoroughly been studied previously, the extended tandem Ig domains are known to associate with increased elasticity in the isoforms [<xref ref-type="bibr" rid="CR19">19</xref>]. Furthermore, this has been described as the reason that the sarcomere in skeletal muscle is more elastic comparted to the sarcomere in cardiac muscle [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par23">The N-terminus of obscurin interacts with several proteins such as titin, slow myosin binding protein C, and myomesin. Furthermore, the 58th and 59th Ig domains in obscurin (coded by exons 67 and 68 of <italic>OBSCN</italic>, with&#x02009;~&#x02009;100% of exon inclusion rate) are known to interact with the Z-band of titin, signifying the essential role&#x000a0;of <italic>OBSCN</italic> in myofibrillogenesis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Further structural studies are needed to reveal the precise effects of the significantly differential exon inclusion events that we have described above. However, as the exons 48&#x02013;58 are distanced from the 5&#x02019; end and the titin interacting sites (<italic>i.e.</italic> exons 67 and 68), the skipping of these exons neither is expected, nor has previously been reported to directly affect the interaction of the obscurin N-terminal with other proteins or to affect the obscurin-titin interaction. The C-terminus of obscurin-A interacts with small Ankyrin 1 (sAnk1) and Ankyrin-B [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. These interactions are essential to the Ca2&#x02009;+&#x02009;homeostasis and the assembly of the dystrophin complex, respectively [<xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, changes in calcium homeostasis and reduction of dystrophin have both been reported in aged skeletal muscles [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. However, even though it can be speculated that the downregulation of obscurin-A in adult skeletal muscles (compared to fetal skeletal muscles) that we have&#x000a0;described above may contribute to these phenotypes, the connection of these phenotypes to obscurin splicing has not specifically been studied.</p><p id="Par24">Finally, RNA splicing regulation information can assist the researchers and the clinicians to understand the clinical impacts of the exonic variants. As for instance we have recently shown how similar exon usage information for <italic>TTN</italic> can be used to explain the disease course in nine titinopathy patients [<xref ref-type="bibr" rid="CR26">26</xref>]. Remarkably, the exon usage information has also been useful in ruling out titinopathy diagnosis for a prenatal case [<xref ref-type="bibr" rid="CR26">26</xref>]. Therefore, we believe that information related to the <italic>OBSCN</italic> exon usage and splicing regulation during skeletal/cardiac muscle development, that we have described in detail here, is potentially useful for clinical interpretation of the exonic mutations in <italic>OBSCN</italic>.</p></sec><sec id="Sec8"><title>Conclusion</title><p id="Par25">In this study we have described several novel exon skipping events that are associated with human cardiac and skeletal muscle development. Additionally, we discovered an alternative final exon usage event associated with human skeletal muscle development. This information allows us to understand the regulation of <italic>OBSCN</italic> splicing during human muscle and heart development. Furthermore, the data is essential for clinical and prognostic interpretation of the <italic>OBSCN</italic> exonic variants and understanding the effects of these variants on the protein expression in different stages of life<italic>.</italic></p><p id="Par26">Our study is strengthened by the thoroughness of the analysis and the support for P-values (and FDRs) that describe how significantly differential the alternative splicing events are during human skeletal and cardiac muscle development. The study is however reliant on the analysis of RNAseq data from a limited selection of muscle types (<italic>e.g.</italic> tibialis anterior and vastus lateralis from the studied postnatal individuals). Therefore, it can be improved by including RNAseq data from more samples and from a more diverse types of muscle tissues in the analysis. Finally, we have developed an interactive visualization tool (using the shiny R package) that can easily be used by the clinicians to check the inclusion level of each <italic>OBSCN</italic> exon during skeletal and cardiac muscle development. The interactive R shiny application is available at <ext-link ext-link-type="uri" xlink:href="http://psivis.it.helsinki.fi:3838/OBSCN_PSIVIS/">http://psivis.it.helsinki.fi:3838/OBSCN_PSIVIS/</ext-link>.</p></sec><sec id="Sec9"><title>Methods</title><sec id="Sec10"><title>In-house data</title><p id="Par27">For prenatal analysis, a trained fetal pathologist collected fetal skeletal muscles (<italic>n</italic>&#x02009;=&#x02009;20) and fetal cardiac muscles (<italic>n</italic>&#x02009;=&#x02009;2) from 2 different fetuses, without muscle pathology, obtained from voluntary termination of pregnancy (TOP).</p><p id="Par28">For postnatal analysis, we collected sample biopsies from an internal cohort of 44 individuals (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). RNA was extracted with the Qiagen RNeasy Plus Universal Mini Kit (Qiagen, Hilden, Germany) according to the instructions provided by the manufacturer. Total RNA-Seq libraries were prepared using the Illumina Ribo-Zero Plus rRNA Depletion Kit (Illumina, Palo Alto, CA, USA) at the Oxford Genomics Center, Welcome Trust Institute, Oxford, United Kingdom and Novogene. Sequencing was performed using NovaSeq 6000 (Illumina), generating over 80 million 150&#x000a0;bp-long reads per sample.</p></sec><sec id="Sec11"><title>External data</title><p id="Par29">In addition to our in-house data, we studied four samples from ENCODE with accession IDs: ENCBS067RNA (fetal skeletal muscle tissue, 19&#x000a0;weeks female), ENCBS068RNA (fetal skeletal muscle tissues, 22&#x000a0;weeks male), ENCBS055RNA (fetal heart tissue, 28&#x000a0;weeks female) and ENCBS056RNA (fetal heart tissue, 19&#x000a0;weeks female) [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Furthermore, for a view on <italic>OBSCN</italic> expression across different human tissues, we obtained data from the GTEx Portal (Analysis Release V8) and dbGaP accession number phs000424.v8.p2 on 09/13/23.</p></sec><sec id="Sec12"><title>RNA-Seq read alignment</title><p id="Par30">The paired RNA-Seq reads were mapped to the Human Genome (GRCh38.p13) using the splice-aware alignment software STAR (V2.7.7a) [<xref ref-type="bibr" rid="CR29">29</xref>]. The software was run in 2-pass mode and most parameters were set to their default values. For the gene annotation, Gencode.v39 was used (further details available in supplemental methods, Additional file 1).</p></sec><sec id="Sec13"><title>Splicing analysis and exon inclusion level estimation</title><p id="Par31">The inclusion levels (i.e. PSI or &#x003a8; values) of all unique exons in human genome, including those of OBSCN gene, were measured using the Intron Exon Retention Estimator (IntEREst) R/Bioconductor package (V1.26.1) [<xref ref-type="bibr" rid="CR30">30</xref>]. IntEREst is a comprehensive RNA-Seq read summarization, differential intron retention and splicing analysis software. It supports tools that measure suitable &#x003a8; values and run statistical differential test for splicing analysis. The inclusion &#x003a8; values were measured for every OBSCN exon. The statistical significance of the increase or decrease of the inclusion levels of OBSCN exons was preformed genome-wide for all exons (except for the first and last exons), however later the results for the OBSCN exons were extracted [<xref ref-type="bibr" rid="CR31">31</xref>]. The statistical test compared the variation of inclusion of each exon relative to the genome-wide variation observed for inclusion of the studied exons. The analysis was adjusted for possible biases introduced by the different sequencing batches by including this parameter as a covariate in the design model of the statistical tests (further details available in supplemental methods, Additional file 1).</p><p id="Par32">In addition to exon skipping/inclusion, we ran a similar analysis for the inclusion of the alternative first and last exons, as well as the only case of alternative 3&#x02019; splicing in <italic>OBSCN</italic> (<italic>i.e.</italic> affecting exons 122 and 123, or 119 and 119a from the meta transcript) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). All the first/last exons of the studied genes (including <italic>OBSCN</italic>) were extracted using biomaRt [<xref ref-type="bibr" rid="CR32">32</xref>]. All <italic>P</italic>-values were adjusted for multiple testing, using the Benjamini&#x02013;Hochberg method [<xref ref-type="bibr" rid="CR33">33</xref>]. An FDR&#x02009;&#x0003c;&#x02009;0.05 cutoff was used to extract the significant results.</p><p id="Par33">Finally, differential gene expression analysis was performed using DESeq2. The analysis was adjusted for the batch effects. The rank correlation of the VST normalized expression levels of the splicing factors (whose IDs were extracted from other studies [<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>]) with the exon inclusion <inline-formula id="IEq31"><alternatives><tex-math id="d33e6358">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\Psi$$\end{document}</tex-math><mml:math id="d33e6363"><mml:mi mathvariant="normal">&#x003a8;</mml:mi></mml:math><inline-graphic xlink:href="13395_2025_374_Article_IEq31.gif"/></alternatives></inline-formula> values was also measured using the Spearman method (further details available in supplemental methods, Additional file 1).</p></sec><sec id="Sec14"><title>Real-time polymerase chain reaction (RT-qPCR) validation</title><p id="Par34">RNA was extracted from two adult muscle samples and two fetal muscle samples using the Qiagen RNeasy Plus Universal Mini Kit (Qiagen, Hilden, Germany) and according to the instructions provided by the manufacturer. The cDNA synthesis was performed using SuperScript III Reverse Transcriptase (Invitrogen TM) and random primers, according to the protocol provided by the manufacturer. The UCSC In-Silico PCR tool and Primer3web v4.1.0 were used to design primers to target either exon-exon junctions or other regions near the junctions (Table <xref rid="MOESM11" ref-type="media">S11</xref>). The RT-qPCR assays were performed using the iQ SYBR Green Supermix (BIO-RAD) and 25&#x000a0;nM of each specific primer. Furthermore, three technical replicates were taken into consideration. For the normalization, 18S was used as the reference gene. The final results were calculated using the &#x00394;&#x00394;Ct method and the relative quantification values were plotted (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>S-T).</p></sec></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13395_2025_374_MOESM1_ESM.pdf"><caption><p>Additional file 1: Supplemental methods and Figures S1-4.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13395_2025_374_MOESM2_ESM.xls"><caption><p>Additional file 2: Table S1. Inclusion levels of OBSCN exons.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="13395_2025_374_MOESM3_ESM.xls"><caption><p>Additional file 3: Table S2. RT-qPCR of inclusion level changes of OBSCN exons in fetal and post-natal skeletal muscle samples.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="13395_2025_374_MOESM4_ESM.xlsx"><caption><p>Additional file 4: Table S3. Canonical exon-exon junction level changes (for non-consecutive exons).</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="13395_2025_374_MOESM5_ESM.xlsx"><caption><p>Additional file 5: Table S4. Non-canonical exon-exon junction level changes (for non-consecutive exons).</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="13395_2025_374_MOESM6_ESM.xlsx"><caption><p>Additional file 6: Table S5. Alternative last exon PSI value changes.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="13395_2025_374_MOESM7_ESM.xls"><caption><p>Additional file 7: Table S6. RT-qPCR of inclusion level changes of long vs short OBSCN isoforms in fetal and post-natal skeletal muscle samples.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="13395_2025_374_MOESM8_ESM.xls"><caption><p>Additional file 8: Table S7. The studied splicing factors.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="13395_2025_374_MOESM9_ESM.xls"><caption><p>Additional file 9: Table S8. Spearman (rank) correlation of expression of splicing factors with exon inclusion levels PSI values across the skeletal muscle samples.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="13395_2025_374_MOESM10_ESM.xls"><caption><p>Additional file 10: Table S9. Spearman (rank) correlation of expression of splicing factors with exon inclusion levels PSI values across the cardiac muscle samples.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="13395_2025_374_MOESM11_ESM.xls"><caption><p>Additional file 11: Table S10. Differential expression analysis results for OBSCN and the studied Splicing Factors.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM12"><media xlink:href="13395_2025_374_MOESM12_ESM.xls"><caption><p>Additional file 12: Table S11. Primer information for the qPCR validation.</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p>The original online version of this article was revised: Following publication of the original article [1], the author noticed that Table 2, especially in the online version, is not readable and has been included as figure. Therefore, the author has requested to update the table, from figure format into table format.</p></fn><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Marco Savarese and Bjarne Udd contributed equally to this work.</p></fn><fn><p><bold>Change history</bold></p><p>4/7/2025</p><p>The original online version of this article was revised: Following publication of the original article [1], the author noticed that Table 2, especially in the online version, is not readable and has been included as figure. Therefore, the author has requested to update the table, from figure format into table format.</p></fn><fn><p><bold>Change history</bold></p><p>4/7/2025</p><p>A Correction to this paper has been published: 10.1186/s13395-025-00380-8</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank the IT Center for Science in Finland (CSC) and the IT Center of the University of Helsinki for providing us with the required computing resources throughout this project.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>AO contributed to the project conceptualization, project supervision, data analysis, validation of the results, development of software, data visualization, and writing of the manuscript. PHJ contributed to the project conceptualization, validation of the results, and review/editing of the manuscript. SNG contributed to validation of the results; data curation and review/editing of the manuscript. MJ contributed to data curation and review/editing of the manuscript. EN contributed to the data analysis. DGA, FM, JCS and MASD provided fetal samples and contributed to data Curation. JS, HT and JT provided adult heart samples and contributed to data curation. PH contributed to the data curation; review/editing of the manuscript, project administration and funding acquisition. MS contributed to the project conceptualization, project administration, project supervision, funding acquisition, validation of the results; data curation and review/editing of the manuscript. BU contributed to the project administration, project supervision, funding acquisition, data curation, and review/editing of the manuscript. All authors read and approved the final manuscript.</p><p>All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open Access funding provided by University of Helsinki (including Helsinki University Central Hospital). We would like to acknowledge that our research was supported by Magnus Ehrnrooth foundation (AO), Samfundet Folkh&#x000e4;lsan i Svenska Finland (MS, BU), Jane and Aatos Erkko foundation (PH), Academy of Finland (MS, BU), European Joint Program on Rare Diseases (BU, FM), Syd&#x000e4;ntutkimuss&#x000e4;&#x000e4;ti&#x000f6; (MS), CoMPaSS-NMD (funded by the European Union under Grant Agreement n&#x000b0; 101080874) and Instituto de Salud Carlos III, Spain (project number AC19/00048 to FM).&#x000a0;Open access was funded by Helsinki University Library.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The in-house RNA-Seq data analysed during the current study are available in the Gene Ex-pression Omnibus repository under accession number GSE270408 (https://www.ncbi.nlm.nih.gov/geo/query/acCite Reference.c.cgi?acc=GSE270408). Due to GDPR the intron and exon level read count tables are publicly available, however further data are available from the corresponding author upon reasonable request. The external RNA-Seq data analysed during the current study are available in the ENCODE repository under accession numbers ENCFF001RMW, ENCFF001RMX, ENCFF001RPA, ENCFF001RPB, ENCFF001ROH, ENCFF001ROG, ENCFF001RPf and ENCFF001RPE (accessible via <ext-link ext-link-type="uri" xlink:href="https://www.encodeproject.org/experiments/ENCSR000AEZ/">https://www.encodeproject.org/experiments/ENCSR000AEZ/</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.encodeproject.org/experiments/ENCSR000AFF/">https://www.encodeproject.org/experiments/ENCSR000AFF/</ext-link>) [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. The analysis scripts are available in GitHub (accessible via <ext-link ext-link-type="uri" xlink:href="https://github.com/gacatag/OBSCN_SCRIPTS">https://github.com/gacatag/OBSCN_SCRIPTS</ext-link>).</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par35">All the muscle-biopsy donors signed an informed consent. The study falls under the ethical HUS/16896/2022. Fetal sampling falls under the approval by Ethics Committee of Clinical Research of the Hospital Universitari Vall d&#x02019;Hebr&#x000f3;n (PR(AMI)210/2021).</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par36">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par37">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>P</given-names></name><name><surname>Ehler</surname><given-names>E</given-names></name><name><surname>Gautel</surname><given-names>M</given-names></name></person-group><article-title>Obscurin, a giant sarcomeric Rho guanine nucleotide exchange factor protein involved in sarcomere assembly</article-title><source>J Cell Biol</source><year>2001</year><volume>154</volume><fpage>123</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">11448995</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Young P, Ehler E, Gautel M. Obscurin, a giant sarcomeric Rho guanine nucleotide exchange factor protein involved in sarcomere assembly. J Cell Biol. 2001;154:123&#x02013;36.<pub-id pub-id-type="pmid">11448995</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuzawa</surname><given-names>A</given-names></name><name><surname>Idowu</surname><given-names>S</given-names></name><name><surname>Gautel</surname><given-names>M</given-names></name></person-group><article-title>Complete human gene structure of obscurin: implications for isoform generation by differential splicing</article-title><source>J Muscle Res Cell Motil</source><year>2006</year><volume>26</volume><fpage>427</fpage><lpage>434</lpage></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Fukuzawa A, Idowu S, Gautel M. Complete human gene structure of obscurin: implications for isoform generation by differential splicing. J Muscle Res Cell Motil. 2006;26:427&#x02013;34.</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Grogan A, Tsakiroglou P, Kontrogianni-Konstantopoulos A. Double the trouble: giant proteins with dual kinase activity in the heart. Biophys Rev. 2020;12:1019&#x02013;29.</mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>MW</given-names></name><name><surname>Raeker</surname><given-names>MO</given-names></name><name><surname>Korytkowski</surname><given-names>KA</given-names></name><name><surname>Sonneman</surname><given-names>KJ</given-names></name></person-group><article-title>Identification, tissue expression and chromosomal localization of human Obscurin-MLCK, a member of the titin and Dbl families of myosin light chain kinases</article-title><source>Gene</source><year>2002</year><volume>282</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">11814696</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Russell MW, Raeker MO, Korytkowski KA, Sonneman KJ. Identification, tissue expression and chromosomal localization of human Obscurin-MLCK, a member of the titin and Dbl families of myosin light chain kinases. Gene. 2002;282:237&#x02013;46.<pub-id pub-id-type="pmid">11814696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Borisov</surname><given-names>AB</given-names></name><name><surname>Raeker</surname><given-names>M&#x000d6;</given-names></name><name><surname>Russell</surname><given-names>MW</given-names></name></person-group><article-title>Developmental expression and differential cellular localization of obscurin and obscurin-associated kinase in cardiac muscle cells</article-title><source>J Cell Biochem</source><year>2008</year><volume>103</volume><fpage>1621</fpage><lpage>1635</lpage><pub-id pub-id-type="pmid">18041765</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Borisov AB, Raeker M&#x000d6;, Russell MW. Developmental expression and differential cellular localization of obscurin and obscurin-associated kinase in cardiac muscle cells. J Cell Biochem. 2008;103:1621&#x02013;35.<pub-id pub-id-type="pmid">18041765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Benian</surname><given-names>GM</given-names></name><name><surname>Mayans</surname><given-names>O</given-names></name></person-group><article-title>Titin and Obscurin: Giants Holding Hands and Discovery of a New Ig Domain Subset</article-title><source>J Mol Biol</source><year>2015</year><volume>427</volume><fpage>707</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">25555989</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Benian GM, Mayans O. Titin and Obscurin: Giants Holding Hands and Discovery of a New Ig Domain Subset. J Mol Biol. 2015;427:707&#x02013;14.<pub-id pub-id-type="pmid">25555989</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Arimura</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><name><surname>Okazaki</surname><given-names>O</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Inagaki</surname><given-names>N</given-names></name><etal/></person-group><article-title>Structural analysis of obscurin gene in hypertrophic cardiomyopathy</article-title><source>Biochem Biophys Res Commun</source><year>2007</year><volume>362</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">17716621</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Arimura T, Matsumoto Y, Okazaki O, Hayashi T, Takahashi M, Inagaki N, et al. Structural analysis of obscurin gene in hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 2007;362:281&#x02013;7.<pub-id pub-id-type="pmid">17716621</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Randazzo</surname><given-names>D</given-names></name><name><surname>Pierantozzi</surname><given-names>E</given-names></name><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Sorrentino</surname><given-names>V</given-names></name></person-group><article-title>The potential of obscurin as a therapeutic target in muscle disorders</article-title><source>Expert Opin Ther Targets</source><year>2017</year><volume>21</volume><fpage>897</fpage><lpage>910</lpage><pub-id pub-id-type="pmid">28756711</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Randazzo D, Pierantozzi E, Rossi D, Sorrentino V. The potential of obscurin as a therapeutic target in muscle disorders. Expert Opin Ther Targets. 2017;21:897&#x02013;910.<pub-id pub-id-type="pmid">28756711</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Rossi D, Palmio J, Evil&#x000e4; A, Galli L, Barone V, Caldwell TA, et al. A novel FLNC frameshift and an OBSCN variant in a family with distal muscular dystrophy. Mayans O, editor. PLOS ONE. 2017;12:e0186642.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera-Serrano</surname><given-names>M</given-names></name><name><surname>Caccavelli</surname><given-names>L</given-names></name><name><surname>Savarese</surname><given-names>M</given-names></name><name><surname>Vihola</surname><given-names>A</given-names></name><name><surname>Jokela</surname><given-names>M</given-names></name><name><surname>Johari</surname><given-names>M</given-names></name><etal/></person-group><article-title>Bi-allelic loss-of-function OBSCN variants predispose individuals to severe recurrent rhabdomyolysis</article-title><source>Brain</source><year>2022</year><volume>145</volume><fpage>3985</fpage><lpage>3998</lpage><pub-id pub-id-type="pmid">34957489</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Cabrera-Serrano M, Caccavelli L, Savarese M, Vihola A, Jokela M, Johari M, et al. Bi-allelic loss-of-function OBSCN variants predispose individuals to severe recurrent rhabdomyolysis. Brain. 2022;145:3985&#x02013;98.<pub-id pub-id-type="pmid">34957489</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Chang W, Cheng J, Allaire JJ, Sievert C, Schloerke B, Xie Y, et al. shiny: Web Application Framework for R. 2024. Available from: <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=shiny">https://CRAN.R-project.org/package=shiny</ext-link></mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>PMA</given-names></name><name><surname>Bousbaa</surname><given-names>H</given-names></name></person-group><article-title>BUB3, beyond the Simple Role of Partner</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><fpage>1084</fpage><pub-id pub-id-type="pmid">35631670</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Silva PMA, Bousbaa H. BUB3, beyond the Simple Role of Partner. Pharmaceutics. 2022;14:1084.<pub-id pub-id-type="pmid">35631670</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>X</given-names></name><etal/></person-group><article-title>Splicing function of mitotic regulators links R-loop&#x02013;mediated DNA damage to tumor cell killing</article-title><source>J Cell Biol</source><year>2015</year><volume>209</volume><fpage>235</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">25918225</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wan Y, Zheng X, Chen H, Guo Y, Jiang H, He X, et al. Splicing function of mitotic regulators links R-loop&#x02013;mediated DNA damage to tumor cell killing. J Cell Biol. 2015;209:235&#x02013;46.<pub-id pub-id-type="pmid">25918225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Mazin</surname><given-names>PV</given-names></name><name><surname>Khaitovich</surname><given-names>P</given-names></name><name><surname>Cardoso-Moreira</surname><given-names>M</given-names></name><name><surname>Kaessmann</surname><given-names>H</given-names></name></person-group><article-title>Alternative splicing during mammalian organ development</article-title><source>Nat Genet</source><year>2021</year><volume>53</volume><fpage>925</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">33941934</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mazin PV, Khaitovich P, Cardoso-Moreira M, Kaessmann H. Alternative splicing during mammalian organ development. Nat Genet. 2021;53:925&#x02013;34.<pub-id pub-id-type="pmid">33941934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Kedlian</surname><given-names>VR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Bolt</surname><given-names>L</given-names></name><name><surname>Tudor</surname><given-names>C</given-names></name><etal/></person-group><article-title>Human skeletal muscle aging atlas</article-title><source>Nat Aging</source><year>2024</year><volume>4</volume><fpage>727</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">38622407</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kedlian VR, Wang Y, Liu T, Chen X, Bolt L, Tudor C, et al. Human skeletal muscle aging atlas. Nat Aging. 2024;4:727&#x02013;44.<pub-id pub-id-type="pmid">38622407</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Pham</surname><given-names>MHC</given-names></name><name><surname>Ko</surname><given-names>KS</given-names></name><name><surname>Rhee</surname><given-names>BD</given-names></name><name><surname>Han</surname><given-names>J</given-names></name></person-group><article-title>Alternative splicing isoforms in health and disease</article-title><source>Pfl&#x000fc;g Arch - Eur J Physiol</source><year>2018</year><volume>470</volume><fpage>995</fpage><lpage>1016</lpage></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kim HK, Pham MHC, Ko KS, Rhee BD, Han J. Alternative splicing isoforms in health and disease. Pfl&#x000fc;g Arch - Eur J Physiol. 2018;470:995&#x02013;1016.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Brinegar AE, Xia Z, Loehr JA, Li W, Rodney GG, Cooper TA. Extensive alternative splicing transitions during postnatal skeletal muscle development are required for calcium handling functions. eLife. 2017;6:e27192.</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Kolmerer</surname><given-names>B</given-names></name><name><surname>Olivieri</surname><given-names>N</given-names></name><name><surname>Witt</surname><given-names>CC</given-names></name><name><surname>Herrmann</surname><given-names>BG</given-names></name><name><surname>Labeit</surname><given-names>S</given-names></name></person-group><article-title>Genomic Organization of M Line Titin and its Tissue-specific Expression in Two Distinct Isoforms</article-title><source>J Mol Biol</source><year>1996</year><volume>256</volume><fpage>556</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">8604138</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Kolmerer B, Olivieri N, Witt CC, Herrmann BG, Labeit S. Genomic Organization of M Line Titin and its Tissue-specific Expression in Two Distinct Isoforms. J Mol Biol. 1996;256:556&#x02013;63.<pub-id pub-id-type="pmid">8604138</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Granzier</surname><given-names>HL</given-names></name><name><surname>Irving</surname><given-names>TC</given-names></name></person-group><article-title>Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments</article-title><source>Biophys J</source><year>1995</year><volume>68</volume><fpage>1027</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">7756523</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Granzier HL, Irving TC. Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments. Biophys J. 1995;68:1027&#x02013;44.<pub-id pub-id-type="pmid">7756523</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname><given-names>PA</given-names></name><name><surname>Liston</surname><given-names>EM</given-names></name><name><surname>Higgins</surname><given-names>DG</given-names></name></person-group><article-title>Molecular evolution of immunoglobulin and fibronectin domains in titin and related muscle proteins</article-title><source>Gene</source><year>1999</year><volume>232</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">10333517</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Kenny PA, Liston EM, Higgins DG. Molecular evolution of immunoglobulin and fibronectin domains in titin and related muscle proteins. Gene. 1999;232:11&#x02013;23.<pub-id pub-id-type="pmid">10333517</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Whitley</surname><given-names>JA</given-names></name><name><surname>Ex-Willey</surname><given-names>AM</given-names></name><name><surname>Marzolf</surname><given-names>DR</given-names></name><name><surname>Ackermann</surname><given-names>MA</given-names></name><name><surname>Tongen</surname><given-names>AL</given-names></name><name><surname>Kokhan</surname><given-names>O</given-names></name><etal/></person-group><article-title>Obscurin is a semi-flexible molecule in solution</article-title><source>Protein Sci</source><year>2019</year><volume>28</volume><fpage>717</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">30666746</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Whitley JA, Ex-Willey AM, Marzolf DR, Ackermann MA, Tongen AL, Kokhan O, et al. Obscurin is a semi-flexible molecule in solution. Protein Sci. 2019;28:717&#x02013;26.<pub-id pub-id-type="pmid">30666746</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Borzok MA, Catino DH, Nicholson JD, Kontrogianni-Konstantopoulos A, Bloch RJ. Mapping the Binding Site on Small Ankyrin 1 for Obscurin. J Biol Chem. 2007;282:32384&#x02013;96.</mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Randazzo</surname><given-names>D</given-names></name><name><surname>Giacomello</surname><given-names>E</given-names></name><name><surname>Lorenzini</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>D</given-names></name><name><surname>Pierantozzi</surname><given-names>E</given-names></name><name><surname>Blaauw</surname><given-names>B</given-names></name><etal/></person-group><article-title>Obscurin is required for ankyrinB-dependent dystrophin localization and sarcolemma integrity</article-title><source>J Cell Biol</source><year>2013</year><volume>200</volume><fpage>523</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">23420875</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Randazzo D, Giacomello E, Lorenzini S, Rossi D, Pierantozzi E, Blaauw B, et al. Obscurin is required for ankyrinB-dependent dystrophin localization and sarcolemma integrity. J Cell Biol. 2013;200:523&#x02013;36.<pub-id pub-id-type="pmid">23420875</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Hughes DC, Marcotte GR, Marshall AG, West DWD, Baehr LM, Wallace MA, et al. Age-related differences in dystrophin: Impact on force transfer proteins, membrane integrity, and Neuromuscular Junction Stability. J Gerontol A Biol Sci Med Sci. 2017;72:640&#x02013;8.</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Terrell</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name></person-group><article-title>Calcium&#x02019;s Role and Signaling in Aging Muscle, Cellular Senescence, and Mineral Interactions</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><fpage>17034</fpage><pub-id pub-id-type="pmid">38069357</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Terrell K, Choi S, Choi S. Calcium&#x02019;s Role and Signaling in Aging Muscle, Cellular Senescence, and Mineral Interactions. Int J Mol Sci. 2023;24:17034.<pub-id pub-id-type="pmid">38069357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Di Feo</surname><given-names>MF</given-names></name><name><surname>Oghabian</surname><given-names>A</given-names></name><name><surname>Nippala</surname><given-names>E</given-names></name><name><surname>Gautel</surname><given-names>M</given-names></name><name><surname>Jungbluth</surname><given-names>H</given-names></name><name><surname>Forzano</surname><given-names>F</given-names></name><etal/></person-group><article-title>Inferring disease course from differential exon usage in the wide titinopathy spectrum</article-title><source>Ann Clin Transl Neurol</source><year>2024</year><volume>11</volume><fpage>2745</fpage><lpage>2755</lpage><pub-id pub-id-type="pmid">39198997</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Di Feo MF, Oghabian A, Nippala E, Gautel M, Jungbluth H, Forzano F, et al. Inferring disease course from differential exon usage in the wide titinopathy spectrum. Ann Clin Transl Neurol. 2024;11:2745&#x02013;55.<pub-id pub-id-type="pmid">39198997</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Gingeras T. ENCSR000AEZ. 2014. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.encodeproject.org/experiments/ENCSR000AEZ/">https://www.encodeproject.org/experiments/ENCSR000AEZ/</ext-link>. Cited 2024 Jul 10.</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Gingeras T. ENCSR000AFF. 2014. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.encodeproject.org/experiments/ENCSR000AFF/">https://www.encodeproject.org/experiments/ENCSR000AFF/</ext-link>. Cited 2024 Jul 10.</mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><etal/></person-group><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><year>2013</year><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">23104886</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15&#x02013;21.<pub-id pub-id-type="pmid">23104886</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Oghabian</surname><given-names>A</given-names></name><name><surname>Greco</surname><given-names>D</given-names></name><name><surname>Frilander</surname><given-names>MJ</given-names></name></person-group><article-title>IntEREst: intron-exon retention estimator</article-title><source>BMC Bioinformatics</source><year>2018</year><volume>19</volume><fpage>130</fpage><pub-id pub-id-type="pmid">29642843</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Oghabian A, Greco D, Frilander MJ. IntEREst: intron-exon retention estimator. BMC Bioinformatics. 2018;19:130.<pub-id pub-id-type="pmid">29642843</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><fpage>550</fpage><pub-id pub-id-type="pmid">25516281</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.<pub-id pub-id-type="pmid">25516281</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Durinck</surname><given-names>S</given-names></name><name><surname>Spellman</surname><given-names>PT</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name></person-group><article-title>Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt</article-title><source>Nat Protoc</source><year>2009</year><volume>4</volume><fpage>1184</fpage><lpage>1191</lpage><pub-id pub-id-type="pmid">19617889</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 2009;4:1184&#x02013;91.<pub-id pub-id-type="pmid">19617889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><article-title>Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title><source>J R Stat Soc Ser B Methodol</source><year>1995</year><volume>57</volume><fpage>289</fpage><lpage>300</lpage></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57:289&#x02013;300.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Seiler</surname><given-names>M</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Agrawal</surname><given-names>AA</given-names></name><name><surname>Palacino</surname><given-names>J</given-names></name><name><surname>Teng</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types</article-title><source>Cell Rep</source><year>2018</year><volume>23</volume><fpage>282</fpage><lpage>296.e4</lpage><pub-id pub-id-type="pmid">29617667</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, et al. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Rep. 2018;23:282-296.e4.<pub-id pub-id-type="pmid">29617667</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Seal</surname><given-names>RL</given-names></name><name><surname>Braschi</surname><given-names>B</given-names></name><name><surname>Gray</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>TEM</given-names></name><name><surname>Tweedie</surname><given-names>S</given-names></name><name><surname>Haim-Vilmovsky</surname><given-names>L</given-names></name><etal/></person-group><article-title>Genenamesorg: the HGNC resources in 2023</article-title><source>Nucleic Acids Res.</source><year>2023</year><volume>51</volume><fpage>D1003</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">36243972</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Seal RL, Braschi B, Gray K, Jones TEM, Tweedie S, Haim-Vilmovsky L, et al. Genenamesorg: the HGNC resources in 2023. Nucleic Acids Res. 2023;51:D1003-9.<pub-id pub-id-type="pmid">36243972</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Giulietti M, Piva F, D&#x02019;Antonio M, D&#x02019;Onorio De Meo P, Paoletti D, Castrignan&#x000f2; T, et al. SpliceAid-F: a database of human splicing factors and their RNA-binding sites. Nucleic Acids Res. 2013;41:D125&#x02013;31.</mixed-citation></ref></ref-list></back></article>